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Abstract: Pulmonary infections may be fatal especially in immunocompromised patients and patients with underlying 
pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive pulmonary disorder, etc. According to the 
WHO, lower respiratory tract infections ranked first amongst the leading causes of death in 2012, and tuberculosis was 
included in the top 10 causes of death in low income countries, placing a considerable strain on their economies and 
healthcare systems. Eradication of lower respiratory infections is arduous, leading to high healthcare costs and requiring 
higher doses of antibiotics to reach optimal concentrations at the site of pulmonary infection for protracted periods. Hence 
direct inhalation to the respiratory epithelium has been investigated extensively in the past decade, and seems to be an 
attractive approach to eradicate and hence overcome this widespread problem. Moreover, engineering inhalation 
formulations wherein the antibiotics are encapsulated within nanoscale carriers could serve to overcome many of the 
limitations faced by conventional antibiotics, like difficulty in treating intracellular pathogens such as mycobacteria spp. 
and salmonella spp., biofilm-associated pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, passage 
through the sputum associated with disorders like cystic fibrosis and chronic obstructive pulmonary disorder, systemic 
side effects following oral/parenteral delivery and inadequate concentrations of antibiotic at the site of infection leading to 
resistance. Encapsulation of antibiotics in nanocarriers may help in providing a protective environment to combat 
antibiotic degradation, confer controlled-release properties, hence reducing dosing frequency, and may increase uptake via 
specific and non-specific targeting modalities. Hence nanotechnology combined with direct administration to the airways 
using commercially available delivery devices, is a highly attractive formulation strategy to eradicate microorganisms 
from the lower respiratory tract, which might otherwise present opportunities for multi-drug resistance. 
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1. BACKGROUND 
 Inhalation is one of the oldest forms of medicament 
delivery dating back to the ancient Egyptian civilization 
where inhalation of vapours of black henbane were 
employed to help breathless patients breathe [1]. Currently, 
this complex route is used primarily for local treatment of 
respiratory diseases, such as cystic fibrosis, chronic 
obstructive pulmonary disease (COPD), bronchiectasis, 
asthma, pneumonia, aspergillosis and tuberculosis. Small 
molecules such as glucocorticoids e.g. budesonide, 
fluticasone, beclometasone; β2-adrenoceptor agonists e.g. 
salbutamol (albuterol), terbutaline, salmeterol, anti- 
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muscarinic bronchodilators e.g. ipratropium, tiotropium and 
antimicrobials e.g. tobramycin, aztreonam, colistin, 
pentamidine have been, and are being successfully 
administered to the lungs for treatment of respiratory 
diseases. In this way, the drug directly reaches the desired 
site of action, leading to the possibility of dose reduction as 
compared to oral and parenteral routes, reducing 
medicament costs and also ensuring a higher concentration 
of drug is retained at the target site [2, 3]. This reduces the 
possible side effects due to decreased systemic exposure 
and helps in achievement of faster onset of action [3]. 
Numerous studies have demonstrated that antimicrobials, 
such as amikacin, tobramycin, rifampicin and amphotericin 
B used  for treatment of lower respiratory tract infections 
caused by organisms like Pseudomonas aeruginosa, 
Candida albicans and Mycobacterium tuberculosis have 
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serious adverse effects, including ototoxicity and 
nephrotoxicity, when administered orally or IV, which are 
ameliorated by a direct pulmonary delivery [4–8]. Due to 
the relatively low metabolic activity in the lung, pulmonary 
delivery is attractive for delivery of drugs which are 
sensitive to gastric pH, enzymes and  metabolizing 
enzymes, particularly those associated with metabolism 
within the liver [9]. It is also useful for drugs belonging to 
Class IV of the Biopharmaceutics Classification System, 
such as amphotericin B, which has low water solubility and 
low membrane permeability, resulting in limited oral 
absorption and hence is administered routinely by the 
invasive IV route [10–12].  
Effective pulmonary drug delivery requires sophisticated 
aerosol formulation approaches and complex delivery 
devices. Moreover, pulmonary delivery is a challenge due 
to the complex anatomy and physiology of the airways, 
restricting access and promoting clearance of inhaled 
materials [3].  
2. PRE-REQUISITES FOR INHALATION: FACTORS 
AFFECTING PULMONARY DRUG DEPOSITION 
The therapeutic effect of an inhaled medicament depends 
largely on its deposition pattern and distribution in the lungs; 
hence, understanding the concepts and mechanisms of these 
processes is of fundamental importance to inhalation 
therapy. Deposition is a process by which particles stick or 
adhere to the surface [13].  
From a formulation viewpoint, the deposition profile is 
largely dependent on the aerosol particle characteristics, 
namely: aerodynamic size, particle size distribution, shape, 
density, electric charge, hygroscopicity and stability. Other 
factors include lung morphology, clearance mechanisms 
(mucociliary and alveolar macrophages), type and severity of 
lung disease, airflow obstruction and patient factors, such as 
inhalation pattern, flow rate, breath-holding time, correct use 
of devices, etc.[14-15]. 
Aerosol particle deposition in the airways is governed by 
three main mechanisms namely: Inertial impaction, 
gravitational sedimentation and Brownian diffusion [15]. 
 
Inertial impaction:  Large particles with high momentum 
(i.e. product of mass and velocity) do not follow the lung 
structure with the flowing air stream and are deflected by the 
airway branching due to inertia and hence convective fluid 
motion leading to deposition on the airway wall [13, 15, 16].  
This occurs mainly at the airway bifurcations of large 
conducting zones of airway and nose, mouth, pharynx, 
larynx and bronchial region. This is a velocity-dependent 
mechanism is the main method for deposition of particles 
greater than 5 µm [17]. 
 
Gravitational sedimentation: This results from the 
gravitational force acting on particles with sufficient mass. 
Deposition due to gravity increases with increasing particle 
size, density and with longer residence time, acting when the 
particle velocity is low resulting in loss of balance between 
the gravitational force and the drag force of air leading to 
subsequent deposition on the lower airway surface. 
Gravitation sedimentation is an important mechanism of 
deposition for particles in the range 0.5-3 µm in small 
conducting airways, like bronchioles and alveoli where the 
air flow rate is low [13, 15, 16]. 
 
Diffusion: This mechanism of deposition predominates for 
particles <0.5 µm and is governed by random Brownian 
motion. Particles are displaced by random motions of air 
molecules, move along the airway streamlines, and deposit 
on contact with the cells by sequential bombardments. 
Deposition by diffusion is directly proportional to particle 
size and occurs in the alveoli and smaller respiratory 
bronchioles, where bulk airflow rate is low or absent [13, 
15].  
 
Aerosol characteristics: 
Aerodynamic diameter is the most important physical 
property of an aerosol that governs the proportion of the dose 
deposited in the airways and can be described as:  
dae = dg (ρe / ρs λ) ½ 
where, dg is the particle geometric diameter, ρe and ρs are the 
effective particle and unit (1g/cm3) density respectively and 
λ is the dynamic shape factor of the particle, i.e. the ratio of 
particle drag force to that of a sphere of equivalent volume 
and is 1 for a perfect sphere. Aerodynamic diameter explains 
the movement of aerosol particles in an air flow not only 
with respect to their geometric diameter but also taking into 
consideration their shape and density [18]. 
Surface roughness of a particle impacts the aerosolization 
efficiency of a dry powder inhalation as it determines the 
interaction forces between the drug particles and between the 
drug and carrier particles (if present) in a formulation. An 
appropriate balance between the interaction forces (during 
mixing/filling) and separation forces (during inhalation) of 
these particles is essential to ensure efficient delivery of the 
medicament to the peripheral lung, when delivered as dry 
powder inhalations [19–21]. Studies have demonstrated that 
an increase in surface roughness of lactose carrier particles 
and sieved sorbitol particles proportionately improves the 
drug carrying capacity of the carrier; however the drug 
particles are held tightly to the carrier particles and hence the 
emitted dose from the inhaler device decreases [19–21]. 
Particle shape plays an important role in the aerodynamics of 
dry powders. Studies have shown that the elongation ratio 
and shape factor of a particle dictates its trajectory in the 
respiratory tract. Rod-shaped particles of carrier lactose 
showed an increase in fine particle fraction compared to 
approximately spherical particles, due to a spatial hindering 
effect [20, 22]. Another study performed on rod-shaped 
cromoglicic acid showed an increased fine particle fraction 
due to their shape being analogous to that of asbestos fibres 
which have a higher susceptibility for pulmonary deposition 
[23, 24]. The study of the relationship between shape and 
surface properties is important as it can affect the 
aerodynamics of dry powders. With higher elongation ratios, 
the contact area between the particles is greater, leading to an 
increased cohesiveness between the particles which may 
ultimately affect the aerodynamic performance of the 
particles.  
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Other than size, shape and surface roughness, deposition is 
also governed by various other formulation parameters, such 
as hygroscopicity, polymorphic form, inter-particular forces 
and surface charge. 
 
3. PULMONARY DRUG DELIVERY DEVICES 
Aerosols are an effective way to deliver medications to the 
pulmonary site. These are two-phased, stable dispersions or 
suspensions of solid or liquid droplets in a gaseous phase 
usually air, and can be generated by a passive breath-driven 
or an active single or multiple dose inhaler [25]. Therapeutic 
aerosols can be delivered using three broad types of devices, 
namely: nebulizers, pressurized metered dose inhalers 
(pMDIs) and dry powder inhalers (DPI), though other 
delivery means have been described. The advantages and 
disadvantages of the different inhaler devices are outlined in 
Table 1. 
  
3.1 Nebulizers 
These were the first devices to be used and they are still 
employed for pulmonary drug delivery by the pediatric and 
geriatric populations for delivering drugs such as salbutamol 
for pediatric asthma, sodium cromoglicate inflammation, 
tobramycin for infections associated with cystic fibrosis and 
COPD, corticosteroids and bronchodilators for severe 
COPD, etc. Nebulizers needs minimum patient skills or 
inhalation/actuation co-ordination [26]. Nebulizers deliver 
drug in droplets generated from solutions or suspensions. 
They have an advantage of delivering large doses during 
tidal breathing. Nebulizers can be classified as: 
Pneumatic or jet nebulizers: These operate on the Bernoulli 
principle by which high velocity compressed air passes 
through narrow orifice creating an area of low pressure at the 
outlet, causing the drug solution to be drawn up from the 
reservoir, forming a liquid film which breaks down into 
liquid droplets due to surface tension. Large droplets are  
retained in the device and a fine mist emitted for inhalation 
via a mouthpiece or facemask [14, 27].  
Ultrasonic nebulizers: These contain a piezoelectric crystal 
which vibrates at a frequency of 1-3MHz producing waves 
which are transmitted to the surface of a drug solution 
leading to formation of standing waves, forming a fountain 
of fine mist. Small droplets, having a size inversely 
proportional to the value of crystal vibrational frequency, are 
produced in the mist [14, 27, 28].  
Vibrating-mesh nebulizers: These contain a piezo-element 
which vibrates a perforated membrane in resonant bending 
mode. The cross-section of the perforations is larger at the 
reservoir side and narrower at the droplet emergence side. 
The size of aerosol droplets produced can be modulated by 
changing the number of perforations and their sizes [29]. 
Electrohydrodynamic atomizers (EHDA):  Also referred to 
as electrospraying, these produce particles suitable for deep 
lung delivery by a low-shear technique wherein application 
of electrical forces in a controlled manner can be useful in 
production of monodispersed droplets of size in the 
nanometric to micrometric range depending on the frequency 
applied during particle production [30].  Studies performed 
by Chattopadhyay et.al [31] compared the atomization of 
DPPC:DPPG:Chol liposomes using jet atomization and 
electrospraying highlighted that on atomization of lower 
concentration of liposomal suspensions (0.1 mg ml-1) using -
jet atomizers only 15% of droplets contained liposomes 
whereas the rest was constituted of only buffer salt particles. 
However, when atomizing using electrospraying higher 
droplet lipid mass concentrations could be obtained [31]. 
 
3.2 Pressurized metered-dose inhalers: pMDIs 
These multi-dose devices have an aluminium canister 
equipped with a metering valve which contains drug 
dissolved or suspended in liquid propellant(s) along with 
other excipients, such as surfactants, e.g. SPAN 85, oleic 
acid and soya lecithin and co-solvents, usually ethanol. 
Actuation of the valve leads to emission of the aerosol as a 
metered dose of drug dissolved or dispersed in propellant, 
usually a hydrofluoroalkane [14, 27, 28, 32].  
 
3.3 Dry Powder Inhalers: DPIs 
Subsequent to the development of pMDIs, dry powder 
inhalers (DPIs) were designed, and these received added 
interest in recent years as ozone-depleting 
chlorofluorocarbon (CFC)-based pMDIs have been phased 
out for environmental reasons. DPIs have no propellant and 
in some respects are more user friendly devices [33].  
DPIs exist in many designs which need for their operation a 
degree of manual dexterity, although simpler DPIs are being 
researched [34]. DPIs dispense a metered quantity of powder 
in an air stream drawn through an inlet system by the 
patient’s inspiration, directing air through the loose powder 
aggregates and forming a drug aerosol cloud. Hence, these 
are passive breath-actuated devices [28, 35]. They are robust, 
portable and convenient in terms of formulation, processing 
and stability as they are a one-phase solid system. They do 
not require to be sterile and avoid the formulation issues of 
nebulizers and pMDIs, particularly for suspension 
formulations, such as sedimentation, flocculation and 
foaming which may impact performance [36].  
DPIs are receiving increasing interest due to drawbacks of 
the use of propellants and the requirement of inhalation-
actuation synchronization when using pMDIs. However, this 
class of devices is subject to strict regulatory manufacturing 
and pharmaceutical standards so that they are reproducible 
and reliable with respect to delivered dose uniformity [37]. 
This requires that a number of characteristics of the DPI 
highlighted below should be satisfied in order to achieve 
patience adherence, device reproducibility/reliability and 
clinical efficacy.  
The characteristics of an ideal DPI can be divided on the 
basis of: 
 Patient acceptance [37–39] 
 Simple operation 
 Portable and easy to carry 
 Multiple dosage reservoir 
 Cost effective and/or reusable 
 Dose counter, dose-ready indicator and an 
audiovisual indicator of doses remaining 
4    Journal Name, 2014, Vol. 0, No. 0 Merchant et al. 
 Patient feedback mechanism to indicate 
successful dosage administration  
 Device reliability and reproducibility with 
respect to dosing [37–41] 
 Consistent and homogeneous dose delivery of 
medicament throughout the life of inhaler, at 
least comparable to a pMDI 
 Accurate and uniform dose delivery of 
medicament over a wide range of inspiratory 
flow rates with minimal variation with respect 
to age, gender and disease state 
 Optimum and reproducible control on 
respirable fractions with high fraction of 
particles in respirable range for deep lung 
delivery 
 Low oropharyngeal deposition with high 
bronchial deposition 
 Efficient device [37–41] 
 Good protection from environmental moisture 
to prevent change in powder aerosol 
characteristics 
 In-process quality control  
 Minimal adhesion between the drug and 
inhalation device 
 Device suitable for a wide range of drugs and 
doses 
 Environmentally accepted device 
No DPI can fulfil all the requirements of an ideal inhaler; 
however, continuous research is being conducted to improve 
their performance to achieve optimal fine particle dosage of 
medicament, with improved patient acceptability. Patient 
education is of utmost importance with regards to use and 
storage of their DPI preparations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Advantages and disadvantages of different inhaler devices 
 
INHALER 
TYPE 
 
NEBULIZER                              
(JET, 
ULTRASONI
C, 
VIBRATING 
MESH) 
 
PRESSURIZ
ED 
METERED- 
DOSE 
INHALER 
(pMDI) 
 
DRY 
POWDER 
INHALER 
(DPI) 
ADVANTAGES Does not 
require 
inhalation 
actuation 
synchronization 
No propellant  
High doses can 
be delivered 
Optimal for 
pediatric, 
geriatric and 
diseased 
patients who 
cannot use other 
devices 
Present 
generation  of 
vibrating-mesh 
nebulizers can 
be battery 
operated and 
hence portable 
(e.g: Aerogen 
Vibronic™) 
Portable and 
compact 
No 
preparation 
required 
No 
contamination 
risk 
Multidose 
(approx. 200 
doses) 
High 
reproducibilit
y between 
doses 
Sealed 
environment 
prevents drug 
degradation 
Cost-effective 
Portable and 
compact 
Does not 
require 
inhalation 
actuation 
synchronization 
No propellant 
Ease in use 
Breath actuated 
No need for 
spacers 
DISADVANTA
GES 
Expensive, 
wasteful 
Contamination 
risk 
Time 
consuming 
Different 
models and 
operating 
conditions lead 
to high 
performance 
variability 
Drug 
formulation 
preparation may 
be necessary 
Nebulizer 
performance 
may decline 
over time 
Requires 
inhalation-
actuation 
synchronizati
on 
High 
oropharyngea
l deposition 
observed 
Maximum 
dosage that 
can be 
administered 
is 
approximatel
y 5 mg 
Young 
children 
require 
valved-
holding 
chamber 
(spacer) 
Propellant- 
based 
Respirable dose 
dependent on 
inspiratory flow 
rate, tidal 
volume, 
breathes/cycle 
etc. 
Respirable dose  
dependent on 
the dry powder 
particle 
properties 
Moisture/electro
static attraction 
may lead to 
powder 
aggregation, 
changing 
aerodynamic 
properties 
and/or causing 
capsule 
softening 
Antimicrobial products for aerosol administration currently 
marketed and in clinical trials are outlined in Tables 2 and 3 
respectively.  
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Table 2: Approved antimicrobial aerosol preparations [42–46]. 
FORMULATION NAME ANTMICROBIAL 
DEVICE AND 
DOSE 
ADVANTAGES INDICATIONS 
TOBI®- Tobramycin 
inhalation solution USP (TIS) 
Novartis 
Tobramycin 
Aminoglycoside 
Nebulization 
PARI-LC® 
PLUS 
300 mg 
nebulized twice 
daily 
Improved lung function, prevention of 
pulmonary exacerbations 
CF 
COPD 
CB 
VAP 
CAP 
BRAMITOB® 
Chiesi Farmaceutici 
Tobramycin 
Aminoglycoside 
Nebulization 
300 mg 
nebulized twice 
daily 
Improved lung function, prevention of 
pulmonary exacerbations 
CF 
CAP 
TOBI®- Tobramycin  
PulmoSphere™  inhalation 
powder USP (TIP) 
Novartis 
Tobramycin 
Aminoglycoside 
Podhaler 
112 mg (28 
mg/capsule) 4 
capsules twice 
daily 
Improved lung function, well tolerated 
and safe, prevention of exacerbations 
CF 
COPD 
CB 
VAP 
CAYSTONE® 
Aztreonam inhalation solution 
(AZLI)  
Gilead Sciences Inc. 
Aztreonam lysine 
Monobactam 
PARI eFlow 
nebulization- 
Altera® handset  
75 mg thrice 
daily 
Safe and efficacious in prevention of 
lung exacerbations, no antibiotic 
resistance evident, superior lung 
function improvement to TIS 
CF 
COLOMYCIN® 
Forest Laboratories 
Colistimethate 
sodium 
Polymyxin 
PARI eFlow® 
nebulization   
80-160 mg twice 
daily 
Eradication of P.aeruginosa CF 
PROMIXINE® (TADIM®) 
Profile Pharma Ltd. 
Colistimethate 
sodium 
Polymyxin 
I-neb® AAD®  
Nebulization  
80-160 mg twice 
daily 
Eradication of P.aeruginosa CF 
COLOBREATHE® 
Forest Laboratories 
Colistimethate 
sodium 
Polymyxin 
Turbospin 
inhaler device-  
 
125 mg twice 
daily 
Safe, well tolerated, efficacy similar to 
TIS 
CF 
NEBUPENT® 
APP Pharmaceutical, LLC 
 
Pentamidine 
isethionate 
 
Antifungal 
Respirgard® II 
Nebulizer 
System 
300 mg/4 weeks 
Safer as compared to its parenteral 
form Pentamidine 300 or Pentacarinat 
Pneumocystis carinii 
pneumonia 
AEROQUIN™ 
Levofloxacin inhalation 
solution 
(Aptalis Pharma, Inc/ Forest 
laboratories) 
Levofloxacin 
Fluoroquinolone 
PARI eFLOW® 
nebulization 
In study 3 dose 
levels-120 mg or 
240 mg once 
daily or 240 mg 
twice a day 
Decrease in P.aeruginosa density, 
reduced need for other anti-
P.aeruginosa antibiotic, well 
tolerated, broad spectrum activity 
Similar efficacy to TOBI in CF 
patients from Phase III clinical trial 
studies 
CF 
COPD 
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Table 3: Aerosol antibiotics in clinical trials [42, 43, 47, 48]. 
FORMULATION NAME ANTIMICROBIAL 
DEVICE AND 
DOSE 
ADVANTAGES INDICATIONS 
ARIKAYCE™ 
Liposomal amikacin for 
inhalation 
Insmed Inc. 
(Phase III clinical trials) 
Amikacin  
aminoglycoside 
PARI eFLOW® 
nebulization 
560 mg once 
daily 
Sustained release of Amikacin, well 
tolerable, reduction in P.aeruginosa 
density 
CF 
Non-tuberculous 
mycobacterial infections 
ABELCETÂ® (Aerosolized 
Abelcet®) 
Amphotericin B lipid complex 
for nebulization 
(Phase II clinical trials) 
Amphotericin B 
 
Antifungal 
50 mg 
nebulized once 
daily for four 
days 
Reduction in parenteral side effects of 
Abelcet® viz. nausea, vomiting, 
disseminated fusariosis and 
withdrawal 
Invasive fungal infections 
in pediatric patients with 
acute leukemia 
CIPROINHALE 
Ciprofloxacin PulmoSphere™ 
inhalation powder (CPIP) 
Bayer HeathCare 
(Phase III clinical trials) 
Ciprofloxacin   
Fluoroquinolone 
Powder 
Inhalation 
In study at 2 
dose levels- 
32.5 mg or 
48.75 mg twice 
daily 
High concentration in the lungs, 
decrease in P.aeruginosa density 
CF 
COPD 
Non-CF bronchiectasis 
4. TYPES OF LUNG INFECTIONS 
Indigenous populations living in affluent countries are 
seriously affected by acute and chronic respiratory diseases 
resulting in a high burden to their health [49]. These diseases 
can be defined as any infectious diseases of the upper or 
lower respiratory tract, wherein, upper respiratory tract 
infections (URTIs) include common cold, tonsillitis, acute 
rhinosinusitis and acute otitis media. Lower respiratory tract 
infections (LRTIs) include acute bronchitis, bronchiolitis, 
pneumonia and tracheitis, and are a major health issue in 
many countries [49, 50]. Bacterial, fungal and viral 
infections occur frequently and play a crucial role in 
progression of chronic pulmonary diseases, such as COPD, 
CB, TB and CF due to acute exacerbations leading to 
substantial long-term consequences, morbidity and mortality 
[49, 51, 52]. 
 
4.1 Bacterial infections 
Bacterial pathogens can be classified on the basis of their 
infection lifestyle in host and, hence can be either 
intracellularly or extracellularly located.  
 
4.1.1 Extracellular pathogens- Most infections in CF, 
COPD, CB, etc., are caused by bacterial pathogens, such as 
Staphylococcus aureus, Escherichia coli and Pseudomonas 
aeruginosa. These organisms live extracellularly and hence 
are easier to eradicate than intracellular infections, which are 
present in special compartments, for instance alveolar 
macrophages and epithelial cells, where delivery of 
antibiotics faces greater challenges. Nevertheless, 
extracellular bacterial pathogens overcome antibiotic 
susceptibility by other means such as genetic modification 
and production of a sessile, slimy covering called a  
 
 
‘biofilm.’ etc. [53]. These are explained briefly in the 
following sections. 
Pseudomonal infections: Psuedomonal infections are 
clinically significant and can lead to life-threatening diseases 
and multiple organ failure [54]. Pseudomonas aeruginosa is 
the most prevalent of this class of pathogens and has been 
long associated with a variety of clinical problems. It is an 
opportunistic nosocomial  pathogen and is the major 
infective organism leading to high mortality and morbidity in 
hospitalized patients [54, 55]. It leads to sepsis in patients in 
the intensive care unit, and is also associated with mortality 
in cases of pulmonary hospital-associated pneumonia (HAP), 
namely ventilator-associated pneumonia (VAP) and 
bronchoscope-associated pneumonia [55]. This pathogen has 
also been associated with exacerbations of pulmonary 
conditions such as cystic fibrosis and COPD, primary 
bacteraemia in AIDS patients, malignant external otitis in 
diabetes’, contact lens keratitis and traumatic 
endophthalmitis to name a few. It is also sometimes involved 
in pulmonary community-acquired pneumonia (CAP), being 
the third most common causative agent after Streptococcus 
pneumoniae and Legionella spp [55]. 
Pseudomonas aeruginosa and Cystic Fibrosis: 
CF manifests a clinical syndrome exemplified by chronic 
infections affecting pulmonary, gastrointestinal, nutritional 
and urinary tracts leading to various abnormalities [56]. 
Pulmonary infections associated with CF are unique as they 
are characterized by various features, such as multiple host 
and parasite functions, metabolic disorder and restriction of 
infection to pulmonary tissue without any evidence of 
spreading systemically [57]. It is a severe monogenic 
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autosomal recessive disorder arising from mutations in a 
single gene on the long arm of chromosome 7 which encodes 
the cystic fibrosis transmembrane conductance regulator 
(CFTR) protein. i.e. a member of ATP binding cassette 
family of transporters [56, 58, 59]. CFTR, a cAMP-regulated 
epithelial chloride channel, is a large glycoprotein channel 
expressed on epithelial cells largely responsible for Cl- 
transport and also for transport of other ions, namely Na+ and 
HCO3-. Movement of water is also a function of this channel, 
maintaining fluidity in the various epithelial linings. In CF 
patients, viscid mucus is formed, due to CFTR dysfunction, 
which leads to a lack of transport of Cl- and water across the 
airway epithelium and excessive Na+ reabsorption. This 
leads to formation of a dehydrated airway surface fluid 
(ASL)/ bronchoalveolar lavage (BAL) fluid. Viscid mucus 
leads to poor mucociliary clearance, entrapment of bacteria 
in the BAL fluid and inflammation [56, 58].  
Despite an impressive understanding of the molecular basis 
and pathophysiology of the disorder, CF still prevails as a 
life-threatening genetic disorder causing many medical 
problems ultimately resulting in premature death [56, 59]. 
Initially CF is associated with gastrointestinal disorders and 
pneumonia due to Staphylococcus aureus or Haemophilis 
influenza. However, these can be eradicated using antibiotics 
and patients lead a relatively normal life with appropriate 
gastrointestinal symptom control. With the advent of P. 
aeruginosa colonization, a myriad of medical disorders 
begin. There is rapid exacerbation and remission of the 
disease and formation of a large number of P. aeruginosa 
cells (up to 108 organisms/ml) in the sputum and the extra 
mucus produced is sufficient to hold the pathogen at the 
pulmonary site, which cannot be killed by the alveolar 
macrophages on their own [60]. Additionally, P. aeruginosa 
adapts to anaerobic growth; obstruction of the bronchioles 
with mucus and low residual oxygen, leading to a low redox 
potential [57]. The organisms shed cell wall components, 
flagella, bacterial DNA and lipopolysaccharide all being 
immunostimulatory lead to a rapid proinflammatory 
response and formation of serotype-specific antibodies in the 
BAL fluid. However, these along with alveolar macrophages 
are ineffective in mediating opsonic uptake and killing of the 
pathogens. A study performed by Fick and colleagues 
showed that P. aeruginosa forms elastase which is capable 
of cleaving human IgG into fragments of less biological 
activity, such as Fab, F(ab’)2 and Fc which have been 
obtained from BAL fluids of CF patients. This has been 
shown to be the reason for failure of the host defence system 
in eradicating the pathogen. Rather, human host-defence 
systems lead to more damage due to loss of granular contents 
from phagocytic cells, polymorphonuclear accumulations, 
excessive interleukin-8 and complement cleavage which 
leads to chronic inflammatory stimulus causing destruction 
of lung tissue [60].  
 
Other microorganisms and Cystic Fibrosis: 
Apart from the abundance of P. aeruginosa, other species of 
microorganism have been identified and isolated from the 
sputum and BAL of CF patients. These include other 
pseudomonal organisms, such as Pseudomonas maltophilia, 
Pseudomonas fluorescens, Pseudomonas alicaligenes and 
Pseudomonas cepacia. The frequency of colonization by 
P.cepacia has increased greatly in the past decade. Infection 
leads to high fever, high leukocyte counts, pulmonary 
complications and is a causative agent leading to death in CF 
patients [57]. 
Other bacteria also found are Staphylococcus aureus, 
Haemophilus influenzae, Sreptococcus pneumoniae, 
Escherichia coli, Klebsiella spp, Proteus spp. etc. However 
these are not as chronic as the pseudomonal species. Acute 
exacerbations in CF are also associated with viruses, 
chlamydia and mycoplasmas. Fungal growths of Aspergillus 
fumigate and Candida albicans have also been isolated [57]. 
 
Pseudomonas aeruginosa and chronic obstructive pulmonary 
disease (COPD): 
Chronic bronchitis is associated with cough and abnormal 
sputum production which on further complication leads to 
obstruction of the airways leading to COPD. COPD is the 3rd 
leading cause of death in the United States and the 6th 
worldwide [61, 62]. Pathogenesis of COPD is unknown; 
however, it has long been associated with cigarette smoking, 
inflammation and infections. Exacerbations of COPD lead to 
a reduction in health-related quality of life, increasing the 
cost of treatment, morbidity and ultimately mortality. 
Bacteria have been found to be the cause of acute 
exacerbation in 50-80% of COPD patients, predominately 
due to Streptococcus pneumonia, Haemophilus influenza and 
Moraxella catarrhalis, as well as other Gram-negative 
organisms such as Pseudomonas and Enterobacteriaceae spp 
[61, 62]. P. aeruginosa is being investigated as a causative 
pathogen for exacerbations in severe COPD cases [63]. It has 
been isolated from 4-15% of adults with severe COPD 
requiring mechanical ventilation. COPD has been associated 
with increased bacterial mutation rates, increased resistance 
to antibiotics and greater biofilm production which is 
comparable to CF even though these two disease have 
completely different pathogenesis [63]. 
In COPD, airways inflammation with neutrophils and 
eosinophils has been evident in induced or expectorated 
sputum and BAL fluids. Neutrophils and eosinophil causing 
inflammation are associated with bacterial and viral 
infections respectively. Increased inflammation leads to 
increased bronchial tone with oedema in the bronchial wall 
and increased mucus production. Other clinical conditions 
associated with inflammation in COPD are cough, dyspnoea, 
increased sputum production and worsening of gas exchange 
due to loss in respiratory functions of the lungs [62].  
 
Pseudomonas aeruginosa and Hospital-acquired pneumonia 
(HAP) and Community-acquired pneumonia (CAP): 
For the past two decades there has been increasing 
prevalence of P. aeruginosa as a hospital-acquired pathogen. 
It is now the most frequently isolated Gram-negative 
organism from patient respiratory tracts and within intensive 
care units.  
Pseudomonas aeruginosa has been isolated from the 
broncho-alveolar lavage (BAL) fluids of patients with 
Vapour-associated pneumonia (VAP). VAP caused by P. 
aeruginosa has a high mortality rate (32 to 43%) even if 
patients are receiving appropriate antibiotic treatment [64].  
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Pseudomonas aeruginosa has also been associated with 
Bronchoscope-associated pneumonia. Bronchoscopes in 
hospitals, due to defects in their design, damage or improper 
disinfection provide an appropriate environment for growth 
of P. aeruginosa [64].  
Pseudomonas aeruginosa has been associated with CAP 
being the third most common pathogen after Streptococcus 
aureus and Legionella pneumophila. However, it is 
associated with severe CAP that necessitates admissions to 
ICU, with an occurrence of 1.8-8.3% and a mortality rate of 
50-100% [64].  
According to the guidelines laid by Infectious Disease 
Society of America/American Thoracic society (IDSA/ATS) 
and European Respiratory society (ERS), levofloxacin is 
recommended as a monotheraphy for CAP and in 
conjunction with β-lactam antibiotic for HAP. However, the 
choice of antibiotics is based on the causative organism [65]. 
4.1.2 Intracellular pathogens: Eradication of intracellular 
infections faces challenges due to the difficulty of access in 
the protective environment within cells. Some organisms, 
such as mycobacteria spp., salmonella spp. and Neisseria 
spp. etc. are primary located in phagocytic intracellular 
compartments, including macrophages, polymorphonuclear 
leukocytes, neutrophils, etc. which recognize pathogen-
associated molecular patterns (PAMPs) present on the 
surface of pathogens which are unique to the pathogen type. 
These proteins expressed on the pathogens are essential for 
their pathogenicity [66–70].  
 
Mycobacterial infections: Tuberculosis (TB), a ubiquitous 
and highly contagious chronic bacterial infection caused by 
the bacillus Mycobacterium tuberculosis has re-emerged  
dramatically since the mid-1980s, particularly since the 
emergence of HIV infection, which renders the host 20-30 
times more susceptible to infection by mycobacterium [71]. 
According to the WHO Global Tuberculosis Report 2013, 
TB affected about 8.6 million people in 2012, of which 1.3 
million died from TB [72]. Additionally, strains of 
mycobacterium which are resistant to the first-line drugs, 
like isoniazid and rifampicin. have a high prevalence (3.6%) 
amongst newly emergent TB cases worldwide [73]. 
Although TB can be both pulmonary and extrapulmonary, 
the pulmonary tract is a major portal of entry for 
mycobacterium, is the initial site of the immune response and 
is the site of resurgence of the disease. Mycobacterium 
tuberculosis has been shown to bind to and internalize into 
the alveolar macrophages, where it enhances its survival by 
suppression of macrophage immune responses ultimately 
leading to the pathogenesis of tuberculosis tuberculosis [68, 
70, 74], and spreads to cause extra-pulmonary TB which 
becomes very difficult to control. 
 
4.2 Fungal infections 
In the past few decades due to concurrent increases in organ 
transplantations, aggressive antineoplastic therapies, and 
immunocompromised patients; the prevalence and severity 
of pulmonary fungal infections has increased [75].  These 
infections have a lethality rate of 30-80% in 
immunocompromised and organ-transplant patients [76, 77]. 
The airways, being the major portal of entry of fungal 
spores, causing such infections, suggests direct pulmonary 
administration of anti-fungal agents to the lungs using 
inhaled drug delivery, could be an attractive way to treat 
invasive pulmonary fungal infections [75, 78].  
Common fungal pathogens which infect the pulmonary tract 
are those that cause [79]: 
(1) Invasive pulmonary aspergillosis- Aspergillus 
fumigatus, Aspergillus flavus, virulent species of 
Aspergillus terreus and A.astus that are resistant to 
treatment by azoles and amphotericin; 
(2) Pulmonary candidiasis- Candida albicans 
(3) Pulmonary mucormycosis- Rhizopus, Mucor and 
Rhizomucor spp 
(4) Pulmonary cryptococcosis- C. gattii and C. 
neoformans 
(5) Pulmonary blastomycosis- B. dermatitidis 
(6) Pulmonary histoplasmosis- H. capsulatum 
(7) Pulmonary coccidioidomycosis- Coccidioides 
immitis and C. posadasii [79] 
Pneumocystis pneumonia has emerged as a serious 
healthcare problem due to the increased incidence of HIV 
which causes weakening of the patients’ immune systems 
leading to infection with opportunistic fungus Pneumocystis 
jirovecii. This infection invades the alveolar lumen in the 
lungs of susceptible hosts, blocking oxygenation, leading to 
death [80]. 
5. LIMITATIONS OF CURRENT ANTIMICROBIAL 
THERAPY 
5.1 Intracellular pathogens 
Intracellularly bacterial infections are major causes of 
morbidity and mortality. Almost every bacterium has shown 
the ability to adapt and develop to form stronger and less 
susceptible variants to current antibiotic treatments, as 
evidenced by the high incidence of multi-drug resistant 
bacterial infections. This represents a considerable public 
health and economic burden as these variants are difficult to 
eradicate and more expensive to treat.  This highlights the 
importance of developing new and improved methods of 
bacterial eradication. However, development of new 
chemotherapy approaches to combat the rapidly growing 
resistant strains of bacteria is too slow, threatening our 
ability to treat infectious diseases in the near future [81]. 
 
5.2 Biofilms 
Microbiological research focuses predominantly on 
planktonic state cells, i.e. bacterial cells floating in culture to 
study antimicrobial activity. However it has now been 
established that in more than 80% of microbial infections the 
bacteria grow as a protected structured community of sessile 
cells encased in a self-produced hydrated polysaccharide 
slimy matrix [82–84]. Initially, a layer is formed at a surface, 
i.e. the foundation of the biofilm made up of 
organic/inorganic substances deposited and adhered to a 
substrate by gravitational sedimentation or settling. This 
provides nutrients and an anchor for the bacteria. Planktonic 
bacteria from the bulk liquid are then adsorbed and start 
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forming micro-colonies onto this conditional layer by 
physical processes such as steric interactions, electrostatic 
interactions and Van der Waal forces or by bacterial 
appendages such as flagellae, pili and fimbriae.  These then 
develop irreversible attachments by secretion of 
polysaccharide intercellular adhesion proteins and divalent 
cations that consolidate the surface-bacteria bond. These 
structures contain channels in which nutrients for the 
bacterial cells are circulated, and hence there is a rapid 
population growth of daughter sessile bacterial cells which 
adapt to the biofilm environment by changes in the 
expression of genes and in the surface properties of bacterial 
cells, and grow together in nascent clusters. The final stage 
of biofilm development is completed by quorum sensing 
(QS) cell signalling mechanisms, wherein stimulation of 
genetic expression takes places leading to production of 
alginate which forms a part of the extracellular matrix of the 
biofilm, along with many other signal molecules that help in 
co-ordination of the biofilm bacteria. These signals govern 
processes such as bacterial dispersion which is essential to 
prevent overgrowth of the rapidly dividing bacteria, and their 
escape and colonization of new niches when nutrients 
become limited and waste products accumulate [85]. 
Numerous mechanisms are involved in the avoidance of 
antibiotic challenges by biofilm-associated bacteria. One 
mechanism is the failure, retardation or reduction in 
penetration and diffusion of antibiotics into the full depth of 
the biofilm due to the presence of a physical polymeric 
barrier. A further mechanism is a change in the 
microenvironment of the biofilm. Studies have shown that 
there are anaerobic niches in the deeper regions of the 
biofilms, rendering some antibiotics, such as those of the 
aminoglycoside class inactive. Moreover, accumulation of 
waste products may cause a change in the pH of the biofilm 
niche which can directly cause inactivation or antagonism of 
certain antibiotics, limiting their activity. Additionally 
alteration in the osmotic environment leads to an osmotic 
stress response, ultimately resulting in a reduction in the 
permeability of bacteria to antibiotics by altering the 
proportion of porins in the bacterial cell wall. A further 
proposed mechanism to explain reduced biofilm 
susceptibility is the development of slow-growing or non-
growing dormant bacterial cells which become less 
susceptible to antibiotics, e.g. penicillin antibiotics which 
target cell-wall synthesis bacteria [82, 83]. 
5.3 Bacterial resistance 
Historically, treatment failures to antibiotics due to 
resistance were not given a great deal of importance as other 
antibiotic classes were available. However, relatively quickly 
multiple resistance to numerous antibiotic developed, which 
now represents a considerable therapeutic challenge. The 
first global report on antibiotic resistance by the WHO in 
2014 revealed a serious threat worldwide and the need for 
urgent interventions to combat an imminent future crisis 
[86]. Multi-drug resistant tuberculosis (MDR-TB) has 
emerged swiftly, representing a global health concern, 
threatening TB control and treatment worldwide [87]. WHO 
has reported a doubling in the people diagnosed with MDR-
TB between 2011 and 2012, with 0.45 million new 
incidences of MDR-TB and an occurrence of 0.17 million 
deaths in 2012 due to MDR-TB [72, 73]. Instances of 
extensively drug resistant (XRD-TB) and totally drug 
resistant (TDR-TB) cases have risen persistently in the past 
decade, posing a major challenge to the limited, time 
consuming treatment options currently available to treat TB. 
Bacterial resistance to antibiotics can be innate or acquired 
by genetic and phenotypic modifications. A speculative 
hypothesis explaining reduced antibiotic susceptibility is the 
development of resistance due to genetic chromosomal 
mutations of the bacteria. These can result in (1) reduced 
permeability or uptake of the antibiotic, e.g. resistance to 
chloramphenicol antibiotics due to decreased permeability 
into Gram-negative bacteria. Resistance to penicillin and 
tetracycline is evident in Neisseria gonorrhoea due to 
reduced permeability of the antibiotics [88]; (2) increased 
efflux activity of the antibiotic from the bacterial cell, e.g. in 
the presence of tetracycline, the TetK gene responsible for 
efflux, transcription and translation is activated leading to an 
increase in the number of efflux pumps and consequently 
resistance to tetracycline antibiotics [89]. Up-regulation of 
the norA gene in S. aureus leads to an increase in efflux 
pumps leading to fluoroquinolone antibiotic resistance; (3) 
enzymatic inactivation of antibiotics, e.g. β-lactamases 
catalysing ring-opening of β-lactam antibiotics. 
Aminoglycoside antibiotics are inactivated by addition of 
acetyl, adenyl and phosphoryl groups onto the antibiotic by 
aminoglycoside-inactivating enzymes [90]; (4) alteration of 
the drug target site, e.g. alterations in the target site of DNA 
gyrase subunit A and B are responsible for resistance against 
fluoroquinolone antibiotics [91]. Resistance against 
rifampicin arises from mutation in the β sub-unit of the RNA 
polymerase site required by the drug to show activity. 
Streptomycin resistance has been evident due to target site 
mutation on the rrs gene encoding 16s rRNA [92], and (5) 
loss of enzymes necessary for activation of the antibiotic, 
e.g. inactivation of the katG gene leads to reduced catalase 
activity and hence ineffective conversion of isoniazid into its 
active hydrazine derivative. Inactivation of pyrazinamidase 
by mutation in the pncA gene required for conversion of 
pyrazinamide to its active form pyrazinoic acid results in 
loss of antimycobacterial activity of the antibiotic [93, 94].  
Further, phenotypic modifications involve sessile bacteria in 
biofilms that grow as spore-like biologically programmed 
bacterial subpopulations which are unique and highly 
protected dormant phenotypes, which are resistant to 
antibiotics in the dormant state. Another type of phenotypic 
modification involves the presence of salicylates, such as 
aspirin which make bacteria, including Pseudomonas, 
Mycobacterium tuberculosis and E.coli etc. less susceptible 
to common antibiotics due to an increased antibiotic efflux 
and reduced permeability, by a reduction in the level of porin 
expression [95].    
 
5.4 Sputum 
Mucus in the healthy lung is 10-30 µm thick in the trachea 
and 2-5 µm thick in the bronchial regions. This thickness 
allows easy diffusion of gas, nutrients, ions, proteins, etc., 
and the entrapment of particulate matter which is then 
efficiently removed by the mucociliary clearance process. 
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Chronic lung diseases, such as COPD, chronic bronchitis, 
asthma and CF are associated with impaired mucociliary 
clearance and necrotic death of epithelial and inflammatory 
cells in patients’ lungs leading to bronchiectasis and 
deposition of thick, stationary, tenacious mucus plaques 
where heavy colonization of bacteria especially by P. 
aeruginosa is evident, due to the availability of a nutrient 
rich environment that is optimal for bacterial growth [96–
98]. This viscoelastic and adhesive mucus secretion acts as a 
physical barrier and hinders diffusion of antibiotics and acts 
as an electrostatic barrier. Necrotic cells contribute to excess 
release of a network of copolymerized polyanionic contents 
including DNA, mucin glycoproteins and F-actin which 
physically bind to polycationic antibiotics, such as 
tobramycin leading to their deactivation  [96, 98, 99].  
Antibiotics delivered for treating bacterial infections 
associated with these diseases needs to penetrate the sputum 
and distribute evenly. Drugs such as ion-channel modulators 
or gene therapeutics which need to reach the epithelial layer 
must first traverse the thick mucus layer to achieve their 
desired activity [100, 101]. 
There are steep hypoxic gradients in the airway sputum 
which have been shown to activate the genes responsible for 
anaerobic respiration of P. aeruginosa, and hence cause a 
conversion of the bacteria from the non-mucoid to the 
resistant extracellular polymeric substance (EPS)-producing 
mucoid mutant [98, 102, 103]. This mucoid mutant secretes 
alginate in which microcolonies of the bacteria are 
embedded, providing increased resistance to phagocytes, 
opsins and antibiotics [98, 102–104]. The  increased 
presence of mucin glycoproteins in the sputum of patients 
immobilizes P. aeruginosa by surface interactions, which 
has increased tolerance to antibiotics resisting clearance from 
these hypoxic mucopurulent masses in the airway [98, 105]. 
The CF sputum is the reason for failure of drug delivery and 
hence treatment  [100, 101]. Moreover, antibodies and 
fragments along with other soluble factors act as molecular 
traps for viral gene delivery, as demonstrated for adenoviral 
gene delivery due to the presence of adenoviral antibodies 
[100]. 
6. DRUG DELIVERY SYSTEMS 
Researchers have made great advances in engineering new 
nanotechnology-based carrier systems for different 
pulmonary applications. The choice of delivery system 
largely depends on factors such as: 
Disease condition: This is a crucial parameter which dictates 
the choice of delivery system. For different disease 
conditions, varied formulations are required to transport the 
drug to the particular site of action and impart desired 
pharmacological effect. Delivery of water insoluble drugs 
and highly unstable drug molecules may be achieved by 
loading them into nano-delivery systems. For the systemic 
delivery of insulin for the treatment of Diabetes Mellitus, 
nanoparticle dry powders have been marketed as Exubera® 
(Pfizer; now withdrawn) and Afrezza™ (MannKind) which 
is a Technosphere™-based inhaled insulin product. Both of 
these need to be deposited in the alveoli, and hence require 
an optimized delivery device [106–108]. On the other hand, 
local administration of anti-tubercular drugs needs a delivery 
system which not only transports drug to the alveolar 
macrophages but also has the capacity of being endocytosed 
by these macrophages [106]. However, endocytosis of β-
agonists leads to their inactivation and clearance leading to 
loss of efficacy, hence formulations with minimal 
macrophage uptake properties would be needed [106]. 
Delivery of nanoparticles encapsulating antibiotics to the 
lung for treatment of infections associated with CF, COPD 
or pneumonia etc. can present a great challenge due to the 
thick viscoelastic mucus barrier in the lung. To traverse this 
barrier, nanoparticles must have a small size and should 
ideally be designed with a muco-inert surface so as to 
prevent their adhesion to mucin fibres which are highly 
prevalent and pose as a severe hurdle to delivery of 
antibiotics to the site of infection in these disease conditions 
[109].  
Retainment of pharmacological effect: The formulation and 
preparation of the delivery system should not affect the 
pharmacological activity of the drug. The release profile of 
the drug should be optimized to achieve maximum drug 
efficacy and duration of activity [108]. 
 
Fate of delivery system: This is important criterion needs 
careful consideration. Varied delivery system engineering 
parameters, such as shape, size, materials, aggregation state, 
surface charge, chemical properties, formulation, etc. may 
each affect the toxicity profiles [110]. The small size of these 
new delivery systems imparts them with new physical and 
chemical properties different from conventional bulk drug 
powders [111]. It has been observed that multi-walled 
carbon-nanotube based delivery systems have the capacity to 
collect in the subpleural regions of the lung, leading to 
pulmonary fibrosis, multifocal granulomatous inflammation, 
diffuse histiocytic and neutrophilic inflammation, intra-
alveolar lipoproteinosis etc. [110, 112]. Inhaled 
nanoparticles can not only cause inflammation and other 
exacerbations, but may also interfere with the functioning of 
the pulmonary system. Nanoparticles fabricated of 
polystyrene, gold or titanium dioxide have been reported to 
alter the function and structure of pulmonary surfactant and 
hence impede its ability to decrease surface tension rapidly 
during a normal breathing cycle [113]. Clearance of 
nanoparticles in alveolar region is mediated by alveolar 
macrophages. These recognize nanoparticles, phagocytize 
them, travel to the mucociliary escalator and are cleared. 
However, this process is very slow and the retention half-life 
of solid particles deposited in the alveolar region of humans 
is 700 days. Moreover, larger particles are not easily 
phagocytized nor are ultrafine nanoparticles [114]. 
The various delivery systems which can be used to deliver 
antimicrobials to the site of infection in the lung are: 
6.1 Liposomes 
Liposomes are lipid-based carrier systems which have been 
widely used as drug carriers for cosmeceutical and 
pharmaceutical applications and are the most studied 
delivery system for the delivery of a variety of therapeutics  
[115, 116]. Liposomes are self-assembling structures which 
due to intrinsic interfacial properties imparted by the 
Pulmonary Delivery of Nano-antimicrobial Therapeutics Journal Name, 2014, Vol. 0, No. 0    11 
phospholipids spontaneously form spherical vesicles in 
aqueous media. These vesicles are made up of one or more 
concentric phospholipid bilayers alternating with aqueous 
compartments, with sizes ranging from 0.05-50 µm. 
Hydrophobic and amphiphilic drugs can be incorporated 
within the lipid bilayers, whereas, hydrophilic drugs can be 
encapsulated in the aqueous compartments/core. They are 
safe, non-toxic, biodegradable, biocompatible delivery 
systems for encapsulation of a wide range of drugs having 
varied properties, including molecular size, charge, 
hydrophobicity etc. They interact with living cells by 
adsorption, endocytosis, lipid exchange and/or fusion [116–
118].  Liposomes can be divided into categories based on the 
basis of their size and lamellarity; namely small unilamellar 
vesicles (SUV), large unilamellar vesicles (LUV) and 
multilamellar vesicles (MLV), or on the basis of their 
properties, for instance immunoliposomes, stealth liposomes, 
proteoliposomes, pH-sensitive liposomes, charged liposomes 
etc. [116, 117, 119]. Liposomes can be prepared using a 
number of techniques, the most frequently used of which are 
the thin-film method, reverse-phase evaporation, solvent 
injection, freeze-thaw extrusion and ultrasonication [119]. 
  
Liposome delivery to the lung:  
These are an attractive delivery system to the lung as they 
can be made of surfactants which are endogenous to the 
pulmonary tract. The first pulmonary-delivered liposomal 
product being Alveofact® (LyomarkPharma), instilled to the 
lung for treatment of pulmonary distress syndrome. 
Deposition of liposomes, aerosolized with jet nebulizers, into 
the non-ciliated peripheral regions of the lung results in 
prolonged greater retention of the liposome-associated drug 
within the lung  [120, 121]. Cationic liposomes have been 
successful in aerosol delivery of gene  [114, 122, 123], while 
liposomes conjugated with cell-penetrating peptides can act 
as potential carriers of macromolecules to the lungs [114]. 
Modification of the liposome surface with O-
stearylamylopectin has been shown to increase lung tissue 
affinity [116], while conjugation of liposomes with 
octaargine or antennapedia enhanced cellular uptake in the 
airway [114].  Conjugating mannose to liposomes produces 
superior macrophage uptake to non-conjugated liposomes, 
with potential application in the treatment of diseases such as 
rheumatoid arthritis, tuberculosis, leishmaniasis, etc. where 
the macrophages play a very important role in the disease  
[124, 125]. Stability of the vesicles, vesicle delivery and the 
size properties of the aerosol cloud are major considerations 
when atomizing liposomes using nebulizers, and are 
functions of both formulation properties and the nebulizer 
system employed. Bridges et.al [126] showed the 
significance of lipid concentration in determining the droplet 
size of the aerosols generated from two different jet 
nebulizers, namely Pari-LC and Sidestream. Increasing the 
egg phosphatidylcholine/cholesterol lipid concentration from 
5 to 80 mg/ml led to a reduction in output of the liposomes 
from both the nebulizers for liposomes of 5 µm, with the 
mean droplet size of the aerosol generated being 2 µm. 
Whereas fluid liposomes could be size reduced in the 
nebulizer and delivered in the aerosol, rigid liposomes failed 
to be aerosolized, whilst increased lipid concentrations 
resulted in a rise in viscosity with subsequent reduction in 
aerosolization [126]. Bridges et al [120] also highlighted the 
importance of liposomal constituents for determining the 
damage caused to liposomes during nebulization by 
ultrasonic and jet nebulizers. Fluid egg phosphatidylcholine 
liposomes were size reduced on aerosolization using both 
devices, which will cause loss of entrapped hydrophilic 
drugs,  whilst incorporation of cholesterol or use of lipids 
which having a high phase transition temperature, such as 
DPPC imparted rigidity to the bilayers, resulting in 
liposomes more resistant to the shearing forces occurring 
during aerosolization [120]. Chattopadhyay et al [127] 
highlighted the importance of bilayer composition, namely 
neutral or charged lipids and presence of cholesterol on the 
morphology and bilayer integrity of small liposomal 
suspensions, size range 80-130 nm, nebulized using a jet 
nebulizer. Aerosolization of the liposomes consisting of 
DPPC, DSPG (charged lipid), DPPC:DSPG:DSPE-PEG and 
DPPC:DSPG:Chol demonstrated that addition of charged 
lipids reduced aggregation due to electrostatic repulsion 
during nebulization, as compared to uncharged liposomes 
(DPPC), however, such liposomes had a greater loss of 
encapsulated dye due to increased membrane rupture. On the 
other hand, addition of cholesterol along with the charged 
lipid (DPPC:DSPG:Chol) helped in reduction of aggregation 
and higher retention of dye (>85%) [127]. Studies have 
emphasized the importance of the nebulizer used in 
conjunction with liposomal systems. Use of a vibrating mesh 
nebulizer Aeroneb® for aerosolization of DPPC liposomes 
encapsulating Iloprost for pulmonary arterial hypertension 
showed significant advantages due to reduced drug loss and 
change in liposomal size compared the jet nebulizer Pari 
LC® star or ultrasonic nebulizer Optineb® [128]. The 
relationship between nebulizer performance and formulation 
development requires in-depth knowledge of formulation 
properties and the working principles of the various 
nebulizer types. An attractive approach would be to deliver 
liposomes by DPIs produced by spray drying the liposomes 
and relying on their hydration in situ on delivery to the moist 
airways [129, 130].  
 
Liposomes and antimicrobials:  
The properties of liposomes can be easily manipulated and a 
variety of including antimicrobials can be incorporated 
within them. By encapsulating antimicrobials into liposomes, 
improved delivery may be achieved, for instance by targeting 
macrophages where infections reside, or due to their small 
size they can pass through biofilms and reach peripheral sites 
for complete bacterial eradication [117, 131]. Rifampicin, an 
anti-mycobacterial drug used for tuberculosis treatment 
shows a very high rate of hepatotoxicity and nephrotoxicity, 
along with other side effects, including thrombocytopenia, 
immune haemolytic anemia and intravascular haemolysis 
due to its high metabolism in these organs leading to 
idiosyncratic metabolites which are toxic to these organs on 
oral delivery [132–136]. Encapsulation of rifampicin into 
pulmonary-delivered liposomes improves its toxicity profile 
and reduces hepatotoxicity [137–139]. Various liposomal 
systems for pulmonary delivery of antifungals, 
antimycobacterials and other antimicrobials have been 
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described in literature, a few of which have reached clinical 
trials, as summarized in Table 4. 
 
 
Table 4: Liposomal antimicrobial therapies under investigation.  
ANTIBIOTIC MICROORGANISM ADVANTAGES 
Amikacin 
Aminoglycoside 
DPPC:Chol liposome 
ARIKAYCE™ 
 
Clinical trials phase III 
Pseudomonas aeruginosa 
(Inhalation-nebulization) 
 
Comparison of Arikayce™ versus placebo nebulized to the lungs showed beneficial 
results as liposomal amikacin had susceptibility to cross mucus and biofilm present in 
patients suffering from CF, hence, sustained and significant improvement in lung 
function and reduction of pseudomonas density [140] 
Amikacin 
 
Aminoglycoside 
 
HSPC:Chol:DSPG (2:1:0.1) 
MiKasome® (NeXstar 
Pharmaceuticals, Inc) 
Mycobacterium tuberculosis 
Increased uptake by the mononuclear phagocyte system showed benefits especially for 
multi-drug resistant M.avium, wherein, increased killing is evident versus free amikacin 
which fails to reach high intracellular effects and shows ototoxicity and nephrotoxicity 
[141–144] 
Tobramycin 
 
Aminoglycoside 
 
Fluidosomes 
(Axentis Pharma) 
 
Clinical Trial II 
Pseudomonas aeruginosa 
Escherichia coli 
Staphylococcus aureus [116] 
Improved management of pulmonary infections was seen on intratracheal administration 
of fluid-based liposomes encapsulated tobramycin [145] 
Riampicin+ Isoniazid 
 
DPPC:Chol 
 
Passively targeted 
Mycobacterium tuberculosis 
 
Increased therapeutic drug level found in the plasma on inhalation administration of a 
single dose in guinea pigs 
Drugs found to localize in the alveolar macrophages of the lungs [146, 147] 
Rifampicin+ Isoniazid 
 
DPPC:Chol:O-
stearylamylopectin: DCP:DSPC-
PEG 2K 
 
Actively targeted 
Mycobacterium tuberculosis 
 
Superior efficacy of the formulations against M.tuberculosis with a reduction in 
mycobacterial CFUs in liver, kidney and lungs. 
Reduction in nephrotoxicity associated with the free drug and normal lung morphology 
observed [137, 146, 148] 
Rifampicin 
 
Egg PC:Chol:O-
stearylamylopectin:DCP or 
Egg PC:Chol: maleylated bovine 
serum albumin: DCP 
 
Actively targeted 
Mycobacterium tuberculosis 
 
The targeted liposomes showed improved lung accumulation specifically improved 
alveolar macrophage uptake and accumulation showing the feasibility of the inhalatory 
mode of delivery for eradication of M. tuberculosis.[146, 149] 
No drug specified 
HSPC:Chol:DCP:MAN 
Actively targeted 
- 
 
Significantly higher internalization and selective targeting to alveolar macrophages in 
vivo with the mannose- linked liposomes compared to non-targeted liposomes [146, 150, 
151]. 
Ciprofloxacin 
Fluoroquinolone 
 
Pseudomonas aeruginosa 
Francisella tularenis 
Brucella melitensis [116] 
Reduction of efflux mechanism and increased bacterial retention as compared to free 
drug on aerosol inhalation 
Free drug was ineffective in treating F. Tularenis [152] 
Polymyxin B 
 
Peptide antibiotic 
Pseudomonas aeruginosa 
 
Intratracheal instillation of liposomal polymyxin B showed higher drug amounts, greater 
retention and pronounced protective effects in lungs as compared to free polymyxin B 
and protection from nephrotoxicity, ototoxicity and neuromuscular blockade [118, 153] 
Dapsone 
 
Sulphone antibiotic 
Pneumocystis 
carinii pneumonia 
 
 
Dapsone nanoliposomes based DPI showed enhanced drug release with deep lung 
penetration due to increase in fine particle fraction to 75% reducing systemic toxicity and 
promising better treatment [140, 154] 
Ciprofloxacin-Fluoroquinolone 
or 
Azithromycin-Macrolide 
Mycobacterium avium 
43-fold greater potency was seen against M.avium compared to free ciprofloxacin due to 
increased negative charge imparted by the liposome formulation of DSPG:Chol [117, 
155] 
CF- cystic fibrosis, TB- Tuberculosis, DPI- dry powder inhalation, DSPG- distearoylphosphatidyl glycerol, DCP- dicetyl phosphate, HSPC-hydrogenated Soy 
Phosphatidylcholine, Egg PC- egg Phosphatidylcholine, Chol- cholesterol, MAN- mannose, CFUs- colony forming units 
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6.2 Polymeric microparticles and nanoparticles 
Microparticles are in the micrometer size range and can be 
classified as microspheres i.e. uniform spheres constructed  
of polymeric matrices, or microcapsules i.e. a thin polymer 
membrane encapsulating an oily core [156]. Nanoparticles  
 
can also be used for pulmonary delivery; however, due to 
their small size they may be exhaled and hence not deposit in 
the airways. To overcome this drawback they can be 
delivered by nebulization after suspending in a suitable 
liquid, with deposition governed by the size characteristics 
of the nebulized droplets, or incorporated into larger carrier 
particles [157]. Microparticles are used as an alternative to  
liposomes, being more readily stable on storage or in the 
biological fluids, and they offer the possibility of modulation 
of release rate [158].  
Polymers are used in different fields such as pharmaceutical, 
biomedicine, tissue engineering, cosmeceuticals, etc. [159]. 
Polymeric microspheres prepared from biodegradable or 
biocompatible, natural or synthetic polymers have been 
studied as delivery systems for pulmonary delivery, to 
control delivery of drugs to the pulmonary tract and to 
protect them from enzymatic degradation. Polymer selection 
is critical for the success of the formulation, with appropriate 
control of drug release. As for all pulmonary delivery, the 
size of the nanoparticles and microparticles and their 
adequate dispersion a critical to ensure  deep lung delivery 
[156, 157]. Particulate systems have a number of key 
parameters, including morphology, size, size distribution, 
porosity, density, surface charge, surface energy, controlled 
or sustained release etc. which are functions of many 
variables to be considered in their formulation and 
manufacture, such as: polymer lengths, surfactants, organic 
solvent, preparation methods, etc. A wide range of natural 
polymers, for instance albumin, collagen and chitosan are 
available, however users must consider a potential lack of 
purity, the presence of homogeneity and the possibility of 
disease transmission. However, these natural polymers can 
be modified, for instance the acylation of chitosan, to  
control release rate. Synthetic polymers, like poly(lactide-co-
glycolide) (PLGA) copolymers, polyacrylates, poly(lactic) 
acid (PLA), poly(butylcyanoacrylate) and poly(lactic-co-
lysine) graft polymers and polyanhydrides are available and 
offer advantages over  natural polymers as they can provide 
sustained/controlled release, and have high purity, 
homogeneity and other desirable properties [153, 156–158]. 
Targeting can also be achieved by using ligands. For 
instance, lectin may be used with polymeric microspheres, as 
it binds to simple/complex carbohydrates on bacterial cell 
walls,  and it has been used against Helicobacter pylori 
infections by conjugation onto gliadin nanoparticles [153]. 
Polymeric nanoparticles can be prepared by various methods 
namely: emulsification-solvent removal, phase coacervation, 
interfacial polymerization and spray drying. The choice of 
method depends on the desired size and properties of 
microsphere to be made, and physiochemical properties of 
drug [158]. 
The mechanism of drug release from nanoparticles is due to 
degradation or erosion of the polymeric matrix. If the 
polymer matrix undergoes degradation, it releases by 
diffusion due to polymeric chain breakage leading to 
channels created in matrix. Erosion of polymer matrix leads 
spontaneous drug release as the polymer is eroded  [158, 
159]. Technical and stability issues regarding the use of 
nanoparticles for delivery of anti-infective agents to the lung 
however prevail. To date, most nanoparticles have been 
aerosolized using nebulizers. However, storage of colloidal 
preparations results in instabilities, such as polymer 
hydrolysis, drug loss, particle-particle interaction of 
nano/microparticles and particle aggregation. Previous 
studies have highlighted the importance of formulation 
development and nanoparticle size on aerosol size and the 
incorporation of particles into nebulized droplets. In addition 
to size, the surface properties of individual particles and their 
concentration play an important role in determining 
formulations release kinetics and the output from the 
nebulizer [160–162].  Dry powder inhaler formulations can 
be achieved by spray drying nanoparticle and microparticle 
dispersions, and this can be an attractive alternative approach 
to ensure the long-term stability of nano/microparticles. 
However, redispersion on aerosolization and in the 
pulmonary fluid are important criteria, and retention of the 
nano/micropaticle size in the lungs post-aerosolization can 
be a challenge [162].  
Polymeric nanoparticles described in literature for 
pulmonary applications in infective disease are summarized 
in Table 5. 
 
 
Table 5: Polymeric microparticles described in literature for delivery of antimicrobials for treating pulmonary infections.
POLYMER ANTIMICROBIAL MICROORGANISM ADVANTAGES 
Polybutyl cyanoacrylate 
nanoparticle 
(PBCA) 
Rifampicin  
Antimycobaterial 
 
Mycobacterium avium 
Staphylococcus aureus 
2-3 fold greater delivery of rifampicin loaded-PBCA to the alveolar 
macrophages leading to 2-fold increase in rifampicin efficacy 
compared to free rifampicin [153, 163] 
PLGA- Nanoembedded 
microparticles 
Tobramycin  
Aminoglycoside 
Pseudomonas 
aeruginosa 
PLGA-tobramycin nanoparticles embedded in respirable lactose 
microparticles and consisting of helper polymers like chitosan 
showed greater mucin interactions and behaved as drug reservoirs to  
achieve sustained drug release [164] 
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Poly(lactide-co-glycolide) 
(PLGA) 
Ciprofloxacin 
Fluoroquinolone 
Staphylococcus aureus 
Pseudomonas 
aeruginosa [140, 153] 
 
Nano-ciprofloxacin formulations achieved sustained release of drug 
directly at the site of pulmonary infection and appropriate 
aerodynamic particle size to achieve deep lung access for the drug 
[140, 165] 
Polyisobutyl cyanoacrylate  
(PIBSA) 
 
Ciprofloxacin 
Fluoroquinolone 
Mycobacterium avium IV administration of Ciprofloxacin loaded- PIBSA showed greater 
activity due to higher uptake in alveolar macrophages compared to 
free ciprofloxacin [117] 
Albumin, 
dipalmitoylphosphatidylcholine 
and lactose (DAL) 
Ceftazidime 
Cephalosporin  
Ciprofloxacin 
Fluroquinolone 
Pseudomonas 
aeruginosa 
DAL based ceftazidime and ciprofloxacin showed better stability 
than nebulized solutions in which these drugs precipitate, successful 
co-deposition at desired site in desired ratio, improved aerodynamics 
and additive antipseudomonal activity was achieved [166] 
Carboxymethyl chitosan (CMC) Ciprofloxacin 
Fluoroquinolone 
Escherichia coli 2-fold increase in antibacterial activity of ciprofloxacin loaded CMC 
compared to free ciprofloxacin was seen due to increased bacterial 
uptake [167] 
 
6.3 Lipid microparticles and nanoparticles- Solid lipid 
nanoparticles 
Lipid microspheres and nanospheres may be used as an 
alternative to polymer microspheres and liposomes. Solid-
lipid nanoparticles (SLNs) range from 50-100 nm and have 
attracted attention in the past 25 years due to the easy 
fabrication techniques. SLNs are viewed as a potential 
pulmonary delivery system due to the low toxicity of 
phospholipids employed, compared to polymer-based  
 
 
 
 
systems, higher tolerability in lungs, prolonged and 
controlled release properties and rapid in-vivo degradation 
compared to PLGA or PLA particles. Their composition 
includes: fatty acids, steroids, triglycerides, partial 
glycerides, waxes that are solids at room temperature as well 
as surfactants to stabilize the SLNs. They can be prepared by 
simple spray drying, ultra-sonication and high pressure 
homogenization as dry powders or dispersions for delivery 
via a nebulizer [114, 153]. Lipid microparticles and 
nanoparticles described in literature are summarized in Table 
6. 
Table 6: Solid lipid nanoparticles described in literature for delivery of antimicrobials for treatment of pulmonary infections. 
SOLID LIPID ANTIMICROBIAL MICROORGANISM ADVANTAGES 
Stearic acid, soya, 
phosphatidyl choline and 
sodium taurocholate 
Tobramycin        
Aminoglycoside 
Ciprofloxacin     
Fluoroquinolone 
Pseudomonas 
aeruginosa 
Increased drug bioavailability and prolonged drug release [153] 
Stearic acid Rifampicin, isoniazid or 
pyrazinamide- 
Antimycobacterials 
Mycobacterium 
tuberculosis 
Increased residence time, increased macrophage uptake and 
lymphatic system delivery achieved, decreased administration 
frequency due to increased bioavailability [153, 168] 
 
6.4 Micelles 
Amphiphilic macromolecules having hydrophobic and 
hydrophilic regions have a tendency to assemble in aqueous 
environments at a concentration greater than the critical 
micellar concentration into nano-sized micelles.  These have 
widespread application within pharmaceutics, as 
hydrophobic drugs can be encapsulated within the 
hydrophobic core of the micelles, allowing formulation at 
concentrations greater than their intrinsic water solubility. 
Moreover, the micelle can provide protection from 
degradation of the drug molecules and release kinetics can be 
manipulated by chemical alterations of the micelle surface, 
e.g. by cross-linking. Micelles can be formed from 
polymers/lipids that have been synthesized to achieve 
specific functionalities, such as targeting [156]. Polymeric  
 
 
 
micelles have been shown to be more stable than 
conventional surfactant micelles, having critical micellar 
concentrations less than 10-6 M [156, 169–171]. One of the 
most prominent reasons for resistance to current antibiotics 
is the downregulation of uptake receptors on the surface of 
microorganisms. It would be an attractive approach to 
encapsulate such antibiotics within self-assembling micelles 
which would not be recognized by the receptor surfaces and 
hence help in intake of antibiotics into resistant bacteria.  
Micellar formulations encapsulating anti-microbial agents 
described in the literature are summarized in Table 7. 
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Table 7: Nanomicelles in literature for delivery of antimicrobials for treatment of pulmonary infections. 
 
POLYMER/ LIPID ANTIMICROBIAL MICROORGANISM ADVANTAGES 
Depolymerized chitosan-
stearic acid 
 
Nebulization 
Amphotericin B 
 
Antifungal 
Candida albicans, Aspergillus 
niger, Aspergillus fumigatus, 
Aspergillus flavus Cryptococcus 
neoformans 
Similar efficacy against all the different fungi 
Retention of encapsulation of amphotericin B after 
nebulization indicating no effect on the physical 
properties of the micelles using a jet nebulizer [172] 
Branched 
polyethyleneimine-Stearic 
acid lipopolymer 
 
Dry powder inhalation 
Rifampicin 
 
Antimycobacterial 
Mycobacterium smegmatis Higher uptake and internalization of the cationic 
nanomicelles encapsulating rifampicin into phagosomal 
compartments of the alveolar macrophage cells THP-1 
due to proton-sponge effect was observed [173] 
 
 
6.5 Large porous carriers 
Large porous carriers, referred to as ‘Trojan particles’ by 
Tsapi et.al [174] are newly engineered micrometer-sized 
particles for inhaled drug delivery. These can be of two types 
namely: 
 
Large porous particles (LPPs):  
These are characterized by a geometric size greater than 4 to 
5 µm and mass density less than 0.1 g/cm3, resulting in in 
formation of particles which have a small aerodynamic 
diameter [42, 174, 175]. These are attractive system for 
pulmonary delivery as they have superior aerodynamic 
properties as compared to conventional particles of the same 
physical size. 60% of the nominal dose of such particles may 
reach the deep lung, and they are not cleared easily by 
alveolar macrophages, due to their large size. Hence they are 
attractive for sustained release of drug in the lungs [42, 176]. 
The highly porous surfaces and relatively large sizes of such 
particles help to decrease their surface energy, compared to 
conventional particle approaches, and hence inter-particulate 
cohesion is reduced and they disperse more easily in 
presence of airflow shear forces [42, 176]. This dispersion 
has low inter-patient variability, as it is independent of 
patients’ peak inspiratory flow [42]. 
Large porous capreomycin particles were manufactured by 
spray drying with L-leucine from a 50% aqueous ethanol 
solution to produce particles having mass median 
aerodynamic diameter (MMAD) of 5 µm. Insufflations 
delivery of these particles to guinea pigs resulted in reduced 
bacterial burdens, decreased alveolar clearance and hence a 
potential to lower the dose and decrease toxic side effects 
[177]. Edwards et.al [178] determined the systemic 
bioavailability of insulin and suppression of blood glucose 
levels, using large porous PLGA particles encapsulating 
insulin, prepared by solvent evaporation techniques. 
Inhalation of large porous insulin particles (mean physical 
diameter 6.8 µm, MMAD 2.15 µm) demonstrated higher 
insulin bioavailaibity and glucose suppression for 96 h than 
non-porous insulin particles (mean diameter 4.4 µm, MMAD 
2.15 µm) which showed lower bioavailabity and glucose 
suppression for only 4 h. These results were attributed to the  
 
 
 
 
reduction in phagocytosis by deep lung alveolar 
macrophages, which are inefficient in removal of particles  
greater than 3 µm, leading to sustained release and greater 
bioavailability of insulin systemically [178]. 
An established engineering technique for preparation of 
LPPs is the Novartis PulmoSphere™ Technology. These are 
manufactured by emulsion-based spray-drying, wherein 
submicron oil in water emulsion droplets are generated by 
high pressure homogenization of perfluorooctyl bromide in 
water. The principal lipid component of PulmoSpheres is 
distearoylphosphatidylcholine (DSPC). Drugs, such as 
tobramycin and amphotericin B are dissolved in the water 
phase of the emulsion [42]. 
PulmoSphere formulations of anti-infectives, namely 
tobramycin, amphotericin B and ciprofloxacin have 
undergone at least Phase II clinical trials II. Tobramycin 
inhalation powder- TIP™ (TOBI® Podhaler®; Novartis 
Pharmaceuticals) is safe and efficacious in treating P. 
aeruginosa lung infections in CF patients, and has now been 
licensed and is marketed in several European countries, 
South America and Canada [42], [43]. A questionnaire 
survey of 39 patients and their parents, as well as 54 
respiratory therapists, revealed that TIP™ (TOBI® 
Podhaler®) was considered to be more convenient and 
acceptable than tobramycin inhalation solution (TIS™ 
TOBI®) [42, 179].  Ciprofloxacin PulmoSpheres (Bayer 
HealthCare) have also shown efficacy for the treatment of P. 
aeruginosa in CF patients. Ciprofloxacin DPI was well 
tolerated in patients with minimal ciprofloxacin systemic 
adverse effects. 40% of the total dose was shown to reach the 
trachea/bronchi and alveolar space of the lungs, with the aim 
of increasing ciprofloxacin retention in the lung [180]. This 
formulation was successful in Phase I clinical trials in 2013 
to evaluate the potential of ciprofloxacin DPI for mild to 
moderate COPD. It also passed Phase II studies to evaluate 
safety and efficacy in patients with CF in May 2014 [47, 
181, 182]. 
 
Large porous nanoparticle aggregates (LPNAPs): 
LPNAPs comprise micron-sized particles consisting of 
nanoparticles (1-100 nm) held together by van der Waals 
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forces or present in matrix having components such as 
biopolymers, surfactants, amino acids, lipids and proteins. 
LPNAPs have been made from a range of materials 
including silica, polystyrene, DPPC, albumin, hydroxypropyl 
cellulose, lactose etc. in sizes ranging from 25 to 1000 nm. 
LPNAPs have similar physical and aerodynamic properties 
to LPPs, and once delivered to the lungs they dissociate to 
form individual nanoparticles [174]. LPNAPS can overcome 
the problems associated with pulmonary delivery of 
nanoparticles, i.e. exhalation due to their small size, yet 
provide the advantages of nanoparticles when they are 
liberated in situ following deposition of the larger particles 
in the lungs. 
 
7. ADVANTAGES OF NANO-ANTIMICROBIALS 
7.1 Protective vesicles preventing antimicrobial 
degradation 
Nanocarriers can be an attractive approach for delivery of 
antimicrobials as they provide a protective environment that 
shields the antibiotic preventing degradation. Antibiotic 
inactivation by enzymes or interactions with other 
components in the biofilm matrix may reduce drug activity 
or cause complete resistance to it.  
Mugabe et.al [183] have demonstrated that gentamicin 
encapsulated in liposomes showed superior activity than 
drug alone for eradication of resistant strains of P. 
aeruginosa isolated from clinical CF patients. Three 
different liposomal formulations: DPPC:Chol, DMPC:Chol 
and DSPC:Chol encapsulating gentamicin showed 
significantly higher antimicrobial activity than drug alone 
and enhanced the susceptibility of P. aeruginosa from highly 
resistant to gentamicin (MIC>16 mg/L) to either 
intermediate (MIC≤8 mg/L) or highly susceptible (MIC≤4 
mg/L) for the non-mucoid and mucoid strains of 
Pseudomonas respectively. The mechanism of enhanced 
activity due to the protection of the drug against enzymatic 
degradation, and ease of diffusion across the bacterial 
envelope [183, 184]. 
Turos et.al [185] evaluated the activity of penicillin 
encapsulated within polyacrylate nanoparticles, prepared by 
free radical emulsion polymerization, against resistant strains 
of S.aureus. Microbiological assays indicated that the 
antimicrobial properties of nanoparticle-encapsulated 
penicillin were retained, whilst free penicillin  completely 
lost activity in the presence of penicillinase [184–186]. 
CF sputum being rich in polyanionic components, namely 
mucin, DNA, F-actin, lipopolysaccharides and lipoteichoic 
acid has been shown to reduce the antimicrobial properties of 
the cationic antibiotics polymyxin and tobramycin, due to 
formation of an electrostatic-attraction complex, hampering 
complete eradication of the bacteria [99, 187, 188]. 
Encapsulation of these antibiotics in liposomes reduces 
formation of the electrostatic complex 100-fold, giving a 4-
fold improved inhibition of P. aeruginosa colonies, 
suggesting a potential application in eradication of chronic 
lung infections associated with CF [184, 187]. 
Co-encapsulation of antimicrobial substances, such as metals 
with antibiotics in liposomes not only reduces the toxicity 
issues associated with metals on human cells but has also 
improved the activity of the co-encapsulated antibiotic [184, 
189–194]. Halwani et.al [189] studied the effect of co-
encapsulating of bismuth–ethanedithiol and tobramycin 
(BiEDT-TOB) in DSPC:Chol liposomes on highly resistant 
strains of P. aeruginosa PA-48913. MIC values for 
liposomal BiEDT-TOB were 0.25 mg/L compared to 1024 
mg/L for non-liposomal drug, which could serve as a new 
strategy for enhancing the antibacterial properties of 
tobramycin against resistant bacteria [189]. Halwani et.al 
[190] have also reported the activity of DPPC:DMPG co-
encapsulated gallium with gentamicin (Ga-GEN) liposomes 
against highly resistant strains of P. aeruginosa PA-48913. 
Liposomal Ga-GEN formulations completely eradicated the 
bacterial isolates growing in planktonic and biofilm 
communities at a concentration as low as 0.94 mg/L. They 
also interfered with the release of virulent factors, alginate 
and biofilm [184, 190, 192].  
 
7.2 Controlled release 
Antimicrobial therapy is hampered by the short availability 
of drug at the target site, potentially limiting treatment 
outcomes. Currently for chronic pulmonary infections, high-
doses and frequent parenteral administration are necessary to 
achieve the pulmonary sputum concentrations required to 
eradicate the chronic colonies of biofilm-associated bacteria 
[195–197]. However, protracted and recurrent administration 
of high dose antibiotics is associated with antibiotic 
resistance [197–199].  Inhaled antibiotics also face 
considerable challenges as they are rapidly cleared from the 
lungs by natural clearance mechanisms, namely exhalation 
for small particles, phagocytosis by macrophage and 
dendritic cells, mucociliary clearance, enzyme degradation 
etc. This may lead to antibiotic exposure at sub-inhibitory 
levels, leading to incomplete eradication of bacterial colonies 
embedded in the protective layers of sputum and biofilms, 
leading to higher incidences of antibiotic resistance [98].  
A logical approach to enhance the delivery of antibiotics for 
treating chronic infections, by increasing their residence 
time, is to load them into appropriately sized carriers which 
could serve to deliver the drug to the site of infection.  
However, chronic administration of the carrier may lead to 
their accumulation in the airways. Despite the phospholipids 
used in the preparation of liposomes sometimes being 
endogenous to the lungs; their repeated administration can 
lead to cumulative doses of lipids in the lungs greater than 
the original surfactant pool, resulting in adverse effects, such 
as phospholipidosis [130, 200, 201]. Hence, excipients 
should be minimised, with nanocarriers designed to deliver 
antimicrobials encapsulated in controlled/sustained/extended 
release vesicles which release drug over extended periods, 
maintaining therapeutic levels in the vicinity of the biofilm, 
improving patient compliance whilst reducing chances for 
development  of resistance [98, 197].  
Although a number of research articles have been published 
on the controlled release of antibiotics given systemically or 
as post-operative implants, few reports are associated with 
controlled release of antibiotics following pulmonary 
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delivery [130, 202–204]. One such study used the 
encapsulation of nafcillin and levofloxacin in PLGA 
nanoparticles coated with calcium phosphate, to achieve 
controlled release of the antibiotics. The nanoparticles 
showed sustained release for 4-6 weeks and inhibited biofilm 
formation with complete deterioration of S.aureus biofilms 
over a 7 day period [205]. 
Another study demonstrated the anti-microbial property of 
gentamicin encapsulated in PLGA nanoparticles. In-vitro 
efficacy of the PLGA encapsulated gentamicin against P. 
aeruginosa biofilm was superior to free drug, due to 
achievement of a sustained level of gentamicin in the 
biofilm. Moreover, peritoneal injection in murine infection 
models showed the effective clearance of bacteria and an 
enhanced anti-biofilm effect by PLGA encapsulated 
gentamicin after 96 h, compared to free gentamicin. Empty 
PLGA nanoparticles did not demonstrate any antimicrobial 
effect against P. aeruginosa [184, 206]. 
Cheow and co-workers have illustrated the importance of 
antibiotic release profiles on the anti-bacterial activity 
against biofilm-associated E.coli. Two nanoparticle systems: 
an extended (slow) release and a biphasic system with an 
initial burst release and subsequent slow release, 
encapsulating the hydrophilic antibiotic levofloxacin were 
prepared, using either poly(caprolactone) (PCL) or PLGA 
polymers. Nanoparticles were prepared using two different 
methods, namely nanoprecipitation and emulsification-
solvent evaporation. It was observed that with the extended-
release nanoparticles encapsulating levofloxacin, the 
concentration of antibiotic was above the MBIC value at all 
times, but was unsuccessful in eradicating biofilm-associated 
bacterial cells. A higher antibiotic resistance was prevalent in 
the biofilm cells with lower initial antibiotic concentration, 
which was then passed onto the progeny leading to 
ineffective eradication.  For the biphasic-release 
nanoparticulate system was better in decelerating occurrence 
of biofilm formation, indicating the importance of a high 
initial local concentration, then an extended release to 
maintain the concentration of drug in the biofilm above the 
MBIC at all times. However, over a 6-day period both 
nanoparticulate antibiotic preparations were unable to 
prevent biofilm growth when a single dose was 
administered. Nevertheless a related study by the same group 
demonstrated the effect of release profile of hydrophobic 
ciprofloxacin encapsulated in PLGA and PCL nanoparticles, 
prepared by the emulsion-solvent evaporation method. 
PLGA encapsulated ciprofloxacin, over a 5-day period, 
showed successful inhibition of the biofilm- associated 
bacteria even at concentration as low as 1/16th of the MBIC, 
indicating this to be a highly effective formulation for 
eradication of biofilm-associated E.coli. [184, 207–209]. 
These studies highlight in considering the susceptibility of 
chronic bacterial infections to nanocarrier formulations of 
antimicrobials, the importance of the formulation 
parameters, such as drug properties, choice of polymer,  
method of preparation of nanoparticles, release profile, etc.  
 
7.3 Non-specific targeting 
Nanoparticles can be targeted passively by selective 
extravasation at the site of infection, due to the increased 
porosity of blood vessel induced by increased inflammatory 
factors [53]. Eradication of intracellular organisms presents 
severe challenges as therapeutic concentrations of 
antimicrobials in intracellular compartments are difficult to 
achieve due to their limited penetration capacity [210, 211]. 
Thus, many antibiotics, such as β-lactam and 
aminoglycoside antibiotics show low concentrations in 
intracellular compartments due to poor penetration and 
acidic and enzymatic degradation. However, water-soluble 
quinolone and macrolide antibiotics, such as clindamycin, 
levofloxacin, etc. attain higher intracellular concentrations as 
opposed to extracellular concentrations [210–212].    
Mycobacterium tuberculosis binds to and internalizes in the 
alveolar macrophages as a survival mechanism, and hence is 
very difficult to eradicate completely. A study of liposome- 
encapsulated clofazimine against TB showed that liposomal 
formulations were much more effective in being taken up 
naturally by the macrophages, where the infection prevails, 
improving treatment outcomes and reducing off-target 
toxicity of the anti-tubercular drug in-vitro and in-vivo [213, 
214]. Liposomal clofazimine was more effective in treatment 
of acute and chronic murine TB, giving a bactericidal effect 
with no re-emergence of Mycobacterium tuberculosis 
infection in mice [213, 214]. Another study by Stoops et al 
showed that lipids have the tendency to strip off the waxy 
trehalose dimycolate armour of Mycobacterium making it 
more susceptible to anti-tubercular drugs hence improving 
their efficacy [215]. 
The fusogenic property of liposomes makes them an 
attractive approach for delivering antibiotics directly to cells, 
due to their potential to fuse with phospholipid cell 
membranes. The fluidity of the liposomes can be achieved 
by lowering the phase transition temperature, by 
incorporation of components of the inactivated Sendai virus 
envelope, using lipids which have the 
phosphatidylethanolamine moiety, lipids with double bonds 
and/or asymmetry in acyl chain, or by addition of cholesterol 
[184, 216–220]. Antibiotics enter Gram-negative bacteria by 
two routes: hydrophobic drugs enter by passive transport via 
the lipopolysaccharide and protein-rich outer membrane; 
whereas hydrophilic drugs enter through the outer membrane 
water-filled porin channels. A reduction in antibiotic 
susceptibility of resistant strains of bacteria has been 
reported due to acquisition of genetic factors which lead to 
changes in the bacterial outer membrane porin channels, 
which strongly impacts the influx of antibiotics and hence 
bacterial susceptibility [219, 221–224].  Nicolosi et al. have 
studied the antimicrobial sensitivity of the glycopeptide 
antibiotic vancomycin against ten wild strains of Gram-
negative bacteria using vancomycin encapsulated in 
fusogenic: (DPPC:DOPE:cholesterol hemisuccinate) and 
non-fusogenic liposomes (DPPC: cholesterol) as well as free 
drug. A significant reduction in MIC was observed for the 
vancomycin encapsulated in fusogenic liposomes for all the 
strains of bacteria tested, with an MIC as low as 6 mg/L for 
strains of E.coli and Acinetobacter baumannii, compared to 
vancomycin encapsulated non-fusogenic liposomes and free 
vancomycin which both had an MIC of 512 mg/L. This was 
due to the fusogenic phospholipid vesicles fusing with the 
18    Journal Name, 2014, Vol. 0, No. 0 Merchant et al. 
E.coli bacterial membrane, as confirmed by scanning and 
transmission electron micrographs [219, 225].   
Beaulac et al. showed that bacterial susceptibility to 
antibiotics encapsulated in liposomes is largely determined 
by the fluidity of the liposomal phospholipid bilayer. In vivo 
studies were performed on the lungs of rats which were 
chronically infected intratracheally with the mucoid variant 
of Pseudomonas aeruginosa (PA 508), which is the most 
common opportunistic organism accelerating chronic 
pulmonary infection in cystic fibrosis patients, and in non-
cystic fibrosis bronchiectasis patients. A significantly 
improved antimicrobial susceptibility was evidenced by a 
dramatic reduction in mucoid bacterial load in the lungs (0-8 
CFU/pair of lungs) for the tobramycin encapsulated in 
DPPC: DMPG liposomes called Fluidosomes™ which had a 
phase transition temperature (Tc) of 29.5°C. Free tobramycin 
and tobramycin encapsulated in rigid DSPC: DMPC 
liposomes (Tc=42°C) showed much higher bacterial loads of 
2x105-4.2x107 and 1.9x105-4.3 x106 CFU/pair of lungs 
respectively, with three doses of 600 µg at 16 h intervals. 
Moreover, distribution studies after the last treatment of the 
liposomal formulation and the free antibiotic showed a high 
level ≥27 µg/mg in lung tissue, and 0.59-0.87 µg/mg of 
tissue detected in the kidneys as opposed to 5.31 µg/mg of 
kidney tissue for the free drug. This suggests that liposome 
encapsulated tobramycin would not only be beneficial for 
management of chronic pulmonary infection, but also in 
reducing the systemic side effects and toxicity associated 
with conventional antibiotics. Moreover, studies performed 
with the DPPC: DMPG liposomes (Tc=33°C) at a lower 
dose regimen of two tobramycin treatments of 240 µg at 16 h 
intervals showed a bacterial load of. 0-3 CFU/pair of lungs 
comparable with the high-dose treatments, whereas free 
tobramycin showed a significantly higher bacterial load of 
1.6x105-1.5x106 CFU/pair of lungs [184, 226]. 
Fluidosomes™-Tobramycin is being developed by Axentis 
Pharma (Switzerland) and has shown good safety and 
efficacy profiles in pre-clinical and Phase II clinical trials 
when compared to the present available marketed treatments 
for management of chronic infection caused by Burkholderia 
cepacia pathogens associated with cystic fibrosis. 
Non-specific approaches to targeting suffer from the 
drawbacks of non-specific drug delivery and uptake, hence 
selectively targeting to the site of infection may represent an 
attractive approach to increase uptake, to achieve higher 
doses to eradicate bacteria at the appropriate site, allow a 
reduction in dose and potentially reduce the potential for 
antimicrobial resistance.  
 
7.4 Specific targeting 
7.4.1 Biofilm targeting- Understanding the generation of 
biofilms at the genetic and molecular levels has informed the 
development of drug delivery systems which may help in 
overcoming this physical barrier to effective antimicrobial 
therapy, and help in better elimination of chronic bacterial 
infections associated with biofilms.  
Li et al. demonstrated the influence of nanoparticle surface 
properties with respect to both surface charge and 
hydrophobicity/hydrophilicity on the penetration of biofilms 
secreted by E. coli strain DH5a. Quantum dots (QD) with 
different functional head groups were synthesized by surface 
modification to obtain neutral, i.e. poly(ethylene glycol)-
appended DHLA-QD, negatively-charged COOH-QD  and 
positively-charged QD which were further designed to be 
hydrophobic, i.e. dimethylhexyl ammonium terminus 
(Hexyl-QD) or hydrophilic i.e. trimethylammonium terminus 
(TTMA-QD). 3-D projection of images obtained from a z-
stack using a confocal laser scanning microscope clearly 
showed that the neutral (PEG-QD) and negative-charged 
COOH-QD did not adhere or penetrate into the EPS of the 
biofilm, demonstrated by the absence of green fluorescence 
indicative of the QD amidst the red, fluorescing bacterial 
cells. Both the hydrophobic and hydrophilic positively-
charged QDs showed a high intensity of green fluorescence 
which did not disappear on washing the biofilms with PBS, 
whilst quantification of penetration profiles of the positively 
charged QDs showed they had travelled through the biofilm 
to a depth of 7.2 µm. Moreover, co-localization of the 
hydrophobic Hexyl-QDs with the bacterial cells indicated 
greater uptake of these compared to the hydrophilic TTMA-
QDs which primarily localized in the EPS of the biofilm. 
Hence this study has shown the importance of charge and 
surface properties, whereby a hydrophobic surface of 
nanoparticles could be engineered to deliver antibiotics for 
eradication of chronic intracellular pathogens, whereas a 
hydrophilic surface modification could serve to target 
enzymes and other biofilm-dissolving drugs, for dispersion 
of biofilms [227]. 
An attractive approach in disassembling the EPS matrix of 
bacterial biofilms, and hence enhancing antibiotic therapy 
was studied by Baelo et al. Ciprofloxacin was loaded into 
PLGA nanoparticles, with and without a coating of DNAse 
enzyme. This enzyme has been found to be very effective in 
disrupting the integrity and viscoelastic nature of the DNA-
rich EPS of biofilms, and greatly improves diffusion through 
it [228, 229]. Ciprofloxacin was encapsulated in PLGA 
coated with DNAse by means of covalent linkage using 
poly-lysine on the surface of PLGA nanoparticles. These 
particles had improved mobility in Pseudomonas aeruginosa 
biofilms in both static and dynamic conditions, providing a 
platform for treatment of biofilm-associated bacteria with 
biofilm disassembling and anti-bacterial agents [229]. 
 
7.4.2 Sputum targeting- The CFTR gene defect discovered in 
1989 has not yet resulted in a cure for CF. Major treatment 
failures have been attributed to the hyper-viscoelastic mucus 
‘sputum’ due to inefficient transport of therapeutics. This 
pathological complication also affects treatment of other 
etiological diseases, such as COPD, chronic bronchiectasis 
and asthma. Numerous studies have been conducted on the 
sputum expectorated from CF patients to understand the 
nature of the matrix microstructure, mesh spacing and its 
components to aid in delivering antibiotics and gene vectors 
through this obstacle.  Suk et al. have shown that densely 
packed low molecular weight PEG imparted ‘muco-
inertness’ to the surface of polystyrene (PS) nanoparticles of 
different sizes. Transport of these nanoparticles through CF 
sputum, studied using multiple particle-tracking analysis, 
showed that the uncoated PS nanoparticles with a charge on 
the surface due to a terminal amine group had a strongly 
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hindered transport, whereas similarly sized nanoparticles 
with a muco-inert surface which showed greater movement 
in time-lapse studies. This was attributed to possible 
polyvalent adhesion interactions between the hydrophobic 
mucin fibres and hydrophobic core of PS nanoparticles, and 
also electrostatic interactions of the positively-charged 
nanoparticles with sputum components, such as DNA, F-
actin etc. all of which were masked when particles were 
densely coated with hydrophilic, uncharged PEG molecules 
[229]. A further study has been conducted by the same 
group, in which the transport of biodegradable, di-block 
copolymers prepared from sebacic acid and methoxy-PEG 
were compared to latex particles in undiluted sputum 
expectorated from CF patients. It was seen that the 
biodegradable muco-inert nanoparticles had a mean square 
displacement 50-fold greater compared to uncoated latex 
particles, and a Fick diffusion model confirmed the 
penetration of the muco-inert PSA-PEG nanoparticles to be 
31% in 30 mins compared to the unmodified particles which 
showed strong immobilization and penetration of only 0.6% 
in CF sputum [230]. These studies demonstrate the 
importance of nanoparticle properties such as surface charge, 
hydrophobicity, molecular weight, size, etc. on the transport  
of particles and the encapsulated drug through the sputum 
[229, 230]. 
 
7.4.3 Macrophage targeting- As highlighted above, alveolar 
macrophages play a major role in combating infections. 
However in chronic infections, bacteria and other organisms 
take these over, locating themselves in the protective 
environment where they multiply and become difficult to 
eradicate with routine antibiotics. To eradicate these 
intracellular infections, directly targeting to the macrophages 
could be a highly effective strategy. Much research has been 
performed to study the potential of PLGA microparticles and 
nanoparticles to target the alveolar macrophages, as they 
may remain membrane bound onto the alveolar macrophages 
for up to 2 weeks [231–239]. Makino et al. showed the 
phagocytic uptake of rifampicin encapsulated in PLGA 
nanoparticles. 19-times higher uptake of rifampicin by the 
macrophage cells in-vitro was found for PLGA-encapsulated 
rifampicin formulation compared to free drug in solution 
[236]. A similar study exploring the reasons for an increased 
uptake of PLGA nanoparticles into macrophage cells, 
concluded that 90% of PLGA nanoparticles encapsulating 
rifampicin were taken up and remained membrane bound 
onto the low pH hydrolase rich regions of the phago-
lysosomes for 13 days, as shown by fluorescence and 
immune-electron microscopy, from where rifampicin is 
released over time. Further studies have confirmed that this 
formulation system was more efficient in eradication of 
mycobacterium bovis infected macrophage RAW cells 
compared to free rifampicin at the same concentration. 
Actively targeting nanoparticles to alveolar macrophages has 
been extensively investigated for treatment of various 
infections associated with tuberculosis, visceral 
leishmaniasis, arthritis, etc. [240–242].  Gelatin 
nanoparticles encapsulating isoniazid with and without 
mannose conjugated to the surface of nanoparticles, required 
for selective delivery to macrophages, have been studied. 
Macrophage-uptake studies showed that mannosylated 
nanoparticles were taken up preferentially into macrophages 
compared to non-mannosylated nanoparticles. The anti-
tubercular activity, studied by inducing TB infection in 
BALB/C mice, showed much lower CFU/ml of spleen when 
the mice were treated with mannosylated gelatin 
nanoparticles encapsulating isoniazid, compared to non-
mannosylated  nanoparticles encapsulating isoniazid and free 
isoniazid. This suggests the macrophage uptake of the drug 
encapsulated in nanoparticles is an important pre-requisite 
for treatment of intracellular infections. Similar results have 
been observed by others, studying conjugation of mannose 
onto SLNs, polypropyleneimine dendrimers, etc [243–245]. 
Higher uptake and retention in lung tissue- Antimicrobial 
lung concentrations are of crucial importance, as a drug 
concentration above the MIC and MBIC are required to 
achieve successful eradication of the infecting pathogens. 
Liposome-encapsulated amphotericin B has been long been 
successfully marketed under the name AmBisome for 
intravenous infusion for the treatment of severe systemic and 
deep mycosis in the lungs. Several studies have been 
performed delivering these liposomes and other lipid-based 
systems via nebulization directly to the pulmonary tract to 
achieve high local concentrations and reduce undesirable 
systemic effects [246–248]. One such study has highlighted 
the beneficial effects of nebulized amphotericin B 
encapsulated in liposomes, compared to Fungizone (sodium 
deoxycholate complex) using a SPAG-2 nebulizer. 
AmBisome showed an eight-time higher concentration in the 
lungs (207 µg/mg lung tissue) than Fungizone (24.4 µg/mg 
lung tissue) using in-vivo in murine models infected with 
Aspergillus fumigatus. Also, with a medium infection load of 
107 CFU/g of tissue, AmBisome produced nearly completely 
eradicate from the lungs (mean CFU/g of lung tissue=0.54); 
however, Fungizone showed no improvement in eradication 
compared to the control group (mean CFU/g of lung 
tissue=3.31 for Fungizone and 5.30 for control). This 
demonstrates the importance of higher lung retention 
achieved with nanotechnology- based vesicles and their 
consequent beneficial effects on eradication of bacteria. 
Clinical trials are on-going for nebulized AmBisome 
(AMBINEB) in prophylaxis of Invasive Pulmonary 
Aspergillosis in patients with Acute Myeloid Leukaemia and 
Allogeneic Haematopoietic Progenitor Cell Transplantation. 
Further clinical trials are being conducted following 
completion of Phase II studies of prophylactic nebulization 
of amphotericin B-lipid complex (Albecet®) in paediatric 
patients with acute leukaemia [246–248]. 
8. DISADVANTAGES OF NANO-ANTIMICROBIALS 
 
8.1 Formulation drawbacks: Nanoparticles present many 
challenges, potentially limiting their progress onto the 
market. Key drawbacks are (1) Scale up and transitional 
development from the laboratory bench to industrial 
production is a challenge due to differences in the properties 
of nanoparticles compared to their bulk counterparts. Smaller 
sizes and commensurate large surface area can lead to high 
chances of aggregation, hindering physical handling at an 
industrial level [249]. (2) Low drug encapsulation is a major 
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limitation, and is often dependent on aqueous/lipid 
solubility, as exemplified by a drug’s logP. (3) Stability of 
nanocarrier-drug formulation may be problematic, for 
instance leakage of drug on storage, changes in size and 
surface properties and, particle-particle interaction and 
aggregation (4) Stability of formulation to aerosolization 
processes, especially by nebulization of nanocarriers 
dispersed in liquid, which may result in particle rupture and 
drug loss and consequently unpredictable deposition patterns 
within the airways.  
8.2 Toxicity of nanoparticles to the lung: With the advent 
of nanoparticle drug delivery in pharmaceutical, biomedicine 
and cosmeceutical areas, the field of nanotoxicology has  
emerged to investigate potential adverse reaction to 
nanoparticles  [53, 250]. Nanomaterial structures, due to 
their very small size and large surface area have a potential 
to be more toxic than conventionally sized bulk samples of 
the same materials. This is due to their deeper lung 
penetrations, large surface/mass ratios, aggregation 
capabilities and low water solubility. It has been seen that 
human alveolar macrophages are not capable of removing 
nanoparticles of size 70 nm and less, leading to their deep 
lung access and entrance into bloodstream through the 
alveolar epithelium, and causing evident inflammation in 
other organs. The aggregation state is another important 
determinant. Aggregates of ultrafine carbon particles at 
concentrations of 1 µg/ml and greater impair the phagocytic 
function of human alveolar macrophage. The large surface 
area/mass ratio enables these nanoparticles to undergo 
various reactions which result in toxicity and cause 
inflammation in animal models, whereas their counterpart 
larger particles have demonstrable safety. This is due to 
novel surface characteristics which may contribute to 
reactions like generation of reactive oxygen species, i.e. free 
radical formation as shown for CuO and SiO2 nanoparticles; 
interlukin-8 cytokine production evident following exposure 
to cobalt or TiO2 nanoparticles; increase in mRNA levels of 
inflammatory markers shown for by yttrium and zinc oxide 
nanoparticles. 
 To study toxicity, regulatory authorities require animal 
studies; however, in-vivo studies are conducted using oral, 
intraperitoneal or dermal routes which do not completely 
portray inhalation effects. In-vitro methods have been 
developed to study toxic effects on airway cells (Calu-3 
human cell line), alveolar epithelium (A549-human cell line) 
or tissues. These are quicker, simpler and less expensive than 
in-vivo tests. However, they do not completely take in 
account lung characteristics, such as microenvironments and 
inhalation effects.[250]. 
CONCLUSION 
 Huge research efforts are being made to overcome the 
drawbacks of conventional antimicrobials used to treat lower 
respiratory tract infections, which are one of the leading causes 
of death worldwide. In light of the increased incidence of multi-
drug resistance to conventional antimicrobials, there is an urgent 
need for better treatment modalities. Moreover, the high rates of 
side effects with prolonged oral and parenteral delivery of 
current antimicrobials and low drug availability at the 
pulmonary site leads to insufficient levels of drug in the sputum 
for eradication of infections. This is one of the greatest reasons 
for failure of current treatments for pulmonary infections. Direct 
delivery of antimicrobials, by inhalation, to the pulmonary tract 
could help in not only reducing side effects, but also in lowering 
the dose required to eradicate the bacterial load and reduce the 
potential for resistance and recurrence of infection. 
Furthermore, targeting therapeutic agents to the intracellular 
pathogens, or to pathogens embedded within protective 
coverings like sputum and biofilms, may be achieved by 
utilizing one of the ever-growing nanotechnology platforms for 
encapsulation of antimicrobials into nanosized vesicles, such as 
liposomes, polymeric nanoparticles or micelles.  Development 
of nanosized drug delivery systems encapsulating antimicrobial 
drugs capable of being directly administered to the lungs could 
result in breakthroughs in the therapy of notoriously difficult to 
treat pulmonary infections. 
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LIST OF ABBREVIATIONS 
BAL Broncho-alveolar lavage 
CAP Community acquired pneumonia 
CB Chronic bronchitis 
CF Cystic fibrosis 
CFU Colony forming units 
CHOL Cholesterol 
COPD Chronic obstructive pulmonary disease 
DCP Dicetyl phosphate 
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
DMPG 1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol 
DOPE 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine 
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DPI Dry powder inhaler 
DSPC 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine 
DSPG 1,2-Distearoyl-sn-glycero-3-phosphoglycerol 
EGG PC Egg phosphatidylcholine 
EPS Extracellular polymeric substance 
GSD Geometric standard deviation 
HLB Hydrophilic-lipophilic balance 
HSPC Hydrogenated soybean phosphatidylcholine 
LPNAPS Large porous nanoparticle aggregates 
LPP Large porous particle 
MAN Mannose 
MBIC Minimum biofilm inhibitory concentration 
MDR-TB Multi-drug resistant tuberculosis 
MIC Minimum inhibitory concentration 
MMAD Mass median aerodynamic diameter 
PCL Poly-epsilon-caprolactone 
PLGA Poly(lactic-co-glycolic acid) 
pMDI Pressurized metered dose inhaler 
QD Quantum dot 
TB Tuberculosis 
TDR-TB Totally drug resistant 
VAP Ventilator-associated pneumonia 
XDR-TB Extensively drug resistant  
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